

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORLED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 May 2001 (17.05.2001)

PCT

(10) International Publication Number
WO 01/34604 A2

(51) International Patent Classification⁷: C07D 473/00

(US). PETTER, Russell, C. [US/US]; 343 Hudson Road, Stow, MA 01775 (US).

(21) International Application Number: PCT/US00/31100

(22) International Filing Date:

13 November 2000 (13.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/165,283 12 November 1999 (12.11.1999) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US 60/165,283 (CON)
Filed on 12 November 1999 (12.11.1999)

(71) Applicant (for all designated States except US): BIO-GEN, INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DOWLING, James, E. [US/US]; 30 Aberdeen Drive, Scituate, MA 02066 (US). ENSINGER, Carol [US/US]; 76 Stonegate Road, Chelmsford, MA 01824 (US). KUMARAVEL, Gnanasambandam [US/US]; 10 Perham Circle, Westford, MA 01886

(74) Agent: MYERS, Louis; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME



(57) Abstract: The invention is based on the discovery that compounds of Formula (I), are unexpectedly highly potent and selective inhibitors of the adenosine A₁ receptor. Adenosine A₁ antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula (I).

ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME

BACKGROUND OF THE INVENTION

The invention relates to antagonists of adenosine receptors and methods of making
5 and using the same in the treatment of diseases.


Adenosine is an intracellular and extracellular messenger generated by all cells in the
body. It is also generated extracellularly by enzymatic conversion. Adenosine binds to and
activates seven transmembrane g-protein coupled receptors, eliciting a variety of
physiological responses. Adenosine itself, substances that mimic the actions of adenosine
10 (agonists), and substances that antagonize its actions have important clinical applications.
Adenosine receptors are divided into four known subtypes (i.e., A₁, A_{2a}, A_{2b}, and A₃). These
subtypes elicit unique and sometimes opposing effects. Activation of the adenosine A₁
receptor, for example, elicits an increase in renal vascular resistance while activation of the
adenosine A_{2a} receptor elicits a decrease in renal vascular resistance.

15 In most organ systems, periods of metabolic stress result in significant increases in
the concentration of adenosine in the tissue. The heart, for instance, produces and releases
adenosine to mediate adaptive responses to stress, such as reductions in heart rate and
coronary vasodilatation. Likewise, adenosine concentrations in kidneys increase in response
to hypoxia, metabolic stress and many nephrotoxic substances. The kidneys also produce
20 adenosine constitutively. The kidneys adjust the amount of constitutively produced
adenosine in order to regulate glomerular filtration and electrolyte reabsorption. Regarding
control of glomerular filtration, activation of A₁ receptors leads to constriction of afferent
arterioles while activation of A_{2a} receptors leads to dilatation of efferent arterioles.
Activation of A_{2a} receptors may also exert vasodilatory effects on the afferent arteriole.
25 Overall, the effect of activation of these glomerular adenosine receptors is to reduce
glomerular filtration rate. In addition, A₁ adenosine receptors are located in the proximal
tubule and distal tubular sites. Activation of these receptors stimulates sodium reabsorption
from the tubular lumen. Accordingly, blocking the effects of adenosine on these receptors
will produce a rise in glomerular filtration rate and an increase in sodium excretion.

SUMMARY OF THE INVENTION


The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of particular subtypes of adenosine receptors. Adenosine antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.

In one embodiment, the invention features a compound of formula (I):



where R_1 and R_2 are independently chosen from: (a) hydrogen; (b) alkyl, alkenyl of not less than 3 carbons, or alkynyl of not less than 3 carbons; wherein the alkyl, alkenyl, or alkynyl is either unsubstituted or functionalized with one or two substituents selected from the group consisting of hydroxy, alkoxy, amino, alkylamino, dialkylamino, heterocyclyl, acylamino, alkylsulfonylamino, and heterocyclylcarbonylamino; and (c) aryl and substituted aryl.

R_3 is a bicyclic or tricyclic group chosen from:




where the bicyclic or tricyclic group can be unsubstituted or can be functionalized with one or more (e.g., one, two, three, or more) substituents chosen from: (a) alkyl, alkenyl, and alkynyl; wherein the alkyl, alkenyl, and alkynyl are either unsubstituted or functionalized with one or more substituents selected from the group consisting of alkoxy, alkoxycarbonyl, alkoxycarbonylaminoalkylamino, aralkoxycarbonyl, -R₅, dialkylamino, heterocyclalkylamino, hydroxy, substituted arylsulfonylaminoalkylamino, and substituted heterocyclaminoalkylamino; (b) acylaminoalkylamino, alkenylamino, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonylalkylamino, alkoxycarbonylaminoacyloxy, alkoxycarbonylaminoalkylamino, alkylamino, amino, aminoacyloxy, carbonyl, -R₅, R₅-alkoxy, R₅-alkylamino, dialkylaminoalkylamino, heterocycl, heterocyclalkylamino, hydroxy, phosphate, substituted arylsulfonylaminoalkylamino, substituted heterocycl, and substituted heterocyclaminoalkylamino.

R₄ is chosen from -H, -C₁₋₄-alkyl, -C₁₋₄-alkyl-CO₂H, and phenyl; and can be unsubstituted or can be functionalized with one or more substituents chosen from halogen, -OH, -OMe, -NH₂, -NO₂ and benzyl, optionally substituted with one, two, or three groups selected from halogen, -OH, -OMe, -NH₂, and -NO₂.

R₅ is chosen from -CH₂COOH, -C(CF₃)₂OH, -CONHNHSO₂CF₃, -CONHOR₄, -CONHSO₂R₄, -CONHSO₂NHR₄, -C(OH)R₄PO₃H₂, -NHCOCF₃, -NHCONHSO₂R₄,

-NHPO₃H₂, -NH₂SO₂R₄, -NH₂SO₂NHCOR₄, -OPO₃H₂, -OSO₃H, -PO(OH)R₄, -PO₃H₂, -SO₃H, -SO₂NHR₄, -SO₃NHCOR₄, -SO₃NHCONHCO₂R₄, and the following:



X₁ and X₂ are chosen, independently, from oxygen (O) and sulfur (S).

5 Z is chosen from a single bond, -O-, -(CH₂)₁₋₃-, -O(CH₂)₁₋₂-, CH₂OCH₂-, -(CH₂)₁₋₂O-, -CH=CHCH₂-, -CH=CH-, and -CH₂CH=CH-.


R₆ is chosen from hydrogen, alkyl, acyl, alkylsulfonyl, aralkyl, substituted aralkyl, substituted alkyl, and heterocyclyl.

10 R₆ is preferably hydrogen. However, when R₆ is methyl or another non-hydrogen substituent, the compounds can be highly selective for inhibition of adenosine A_{2a} receptors.

In certain embodiments, R₁ and R₂ can be the same or different alkyl groups. For example, one or both can be n-propyl.


In some embodiments, Z is a single bond.

In one embodiment, R₃ is chosen from the following bicyclic and tricyclic structures:



and is functionalized with one or more substituents chosen from carbonyl, hydroxy, alkenyl, alkenyloxy, hydroxyalkyl, carboxy, carboxyalkenyl, carboxyalkyl, aminoacyloxy, carboxyalkoxy, dialkylaminoalkenyl, and dialkylaminoalkyl.


In another embodiment, R₃ is:



and is functionalized with one or more substituents chosen from carbonyl, hydroxy, alkenyl,

carboxyalkenyl, hydroxyalkyl, dialkylaminoalkenyl, and dialkylaminoalkyl. Thus, for example, the compound can be 8-(5-Hydroxy-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; 8-(5-Hydroxymethyl-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; 8-[5-(3-Dimethylaminopropylidene)-tricyclo[2.2.1.0^{2,6}]hept-3-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; or 8-[5-(3-Dimethylaminopropyl)-tricyclo[2.2.1.0^{2,6}]hept-3-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

In still another embodiment, **R₃** is:



and is functionalized with one or more substituents chosen from hydroxy, carbonyl, alkyl, -**R₅**, **R₅**-alkyl, dialkylaminoalkylamino, alkoxycarbonylalkylamino, **R₅**-alkylamino, heterocyclyl, alkenylamino, amino, alkylamino, heterocyclylalkylamino, acylaminoalkylamino, phosphate, heterocyclylaminoalkylamino, and heterocyclylaminoalkylaminoalkyl.

In yet another embodiment, **R₃** is:



and is functionalized with one or more substituents chosen from hydroxy, -**R₅**, **R₅**-alkyl, and hydroxyalkyl. Thus, for example, the compound can be 4-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]octane-1-carboxylic acid.

In another embodiment, **R₃** is:




and is functionalized with one or more substituents chosen from alkyl, hydroxy, carbonyl, -**R₅**, and **R₅**-alkyl. Thus, for example, the compound can be 8-(4-Hydroxy-bicyclo[3.2.1]oct-6-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; or 8-(4-Oxo-bicyclo[3.2.1]oct-6-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

In still another embodiment, R_3 is:




and is functionalized with one or more substituents chosen from carbonyl, hydroxy, dialkylaminoalkylamino, -R5, and substituted heterocyclaminoalkylaminoalkyl. Thus, for example, the compound can be 8-[8-(2-Dimethylaminoethylamino)-bicyclo[3.2.1]oct-3-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; or 8-(8-Hydroxy-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

In yet another embodiment, R_3 is:




and is functionalized with one or more substituents chosen from carbonyl, hydroxy, and -R5. Thus, for example, the compound can be 8-(3-Hydroxy-bicyclo[3.2.1]oct-8-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

In yet another embodiment, R_3 is selected from bicycles:



and is functionalized with one or more substituents chosen from hydroxyalkyl, hydroxy, and alkoxycarbonyl. Thus, for example, the compound can be 8-(8-Oxa-bicyclo[3.2.1]oct-6-en-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

In yet another embodiment, R_3 is:



and is functionalized with one or more substituents chosen from carbonyl,

aralkyloxycarbonylalkyl, and alkoxycarbonylalkyl. Thus, for example, the compound can be 8-(2-Oxo-3-aza-bicyclo[3.2.1]oct-8-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

The compound can be, for example, in a form of an achiral compound, a racemate, an optically active compound, a pure diastereomer, a mixture of diastereomers, or a pharmacologically acceptable addition salt.

The compounds of this invention can also be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those that increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism, and/or alter rate of excretion. Examples of these modifications include, but are not limited to, esterification with polyethylene glycols, derivatization with pivalates or fatty acid substituents, conversion to carbamates, hydroxylation of aromatic rings, and heteroatom-substitution in aromatic rings.

The invention also features a medicament composition including any of the above compounds, alone or in a combination, together with a suitable excipient.

The invention also features a method of treating a subject suffering from a condition characterized by an elevated adenosine concentration and/or increased sensitivity to adenosine and/or elevated adenosine receptor number or coupling efficiency. The method includes the step of administering to the subject an amount of any of the above compounds to be effective as an adenosine A₁ receptor antagonist. The condition can be, for example, a cardiac and circulatory disorder, a degenerative disorder of the central nervous system, a respiratory disorder, a disease for which diuretic treatment is indicated, hypertension, Parkinson's disease, depression, traumatic brain damage, post-stroke neurological deficit, respiratory depression, neonatal brain trauma, dyslexia, hyperactivity, cystic fibrosis, cirrhotic ascites, neonatal apnea, renal failure, diabetes, asthma, an edematous condition, congestive heart failure, or renal dysfunction associated with diuretic use in congestive heart failure.

The invention also features a method of making 8-substituted xanthines. The method includes the steps of obtaining a N7,C8-dihydroxanthine, protecting the N7 position of the xanthine (e.g., as a THP or BOM ether); deprotonating the C8 position with strong base (such as lithium di-isopropyl amide or n-butyl lithium) to generate an anion; trapping the anion

with a carboxyl, carbonyl, aldehyde, or ketone compound; and deprotecting the protected N7 position to obtain an 8-substituted xanthine.

As used herein, an "alkyl" group is a saturated aliphatic hydrocarbon group. An alkyl group can be straight or branched, and can have, for example, from 1 to 6 carbon atoms in a chain. Examples of straight chain alkyl groups include, but are not limited to, ethyl and butyl. Examples of branched alkyl groups include, but are not limited to, isopropyl and t-butyl.

An "alkenyl" group is an aliphatic carbon group that has at least one double bond. An alkenyl group can be straight or branched, and can have, for example, from 3 to 6 carbon atoms in a chain and 1 or 2 double bonds. Examples of alkenyl groups include, but are not limited to, allyl and isoprenyl.

An "alkynyl" group is an aliphatic carbon group that has at least one triple bond. An alkynyl group can be straight or branched, and can have, for example, from 3 to 6 carbon atoms in a chain and 1 to 2 triple bonds. Examples of alkynyl groups include, but are not limited to, propargyl and butynyl.

An "aryl" group is a phenyl or naphthyl group, or a derivative thereof. A "substituted aryl" group is an aryl group that is substituted with one or more substituents such as alkyl, alkoxy, amino, nitro, carboxy, carboalkoxy, cyano, alkylamino, dialkylamino, halo, hydroxy, hydroxyalkyl, mercaptyl, alkylmercaptlyl, trihaloalkyl, carboxyalkyl, sulfoxy, or carbamoyl.

An "aralkyl" group is an alkyl group that is substituted with an aryl group. An example of an aralkyl group is benzyl.

A "cycloalkyl" group is an aliphatic ring of, for example, 3 to 8 carbon atoms. Examples of cycloalkyl groups include cyclopropyl and cyclohexyl.

An "acyl" group is a straight or branched alkyl-C(=O)- group or a formyl group. Examples of acyl groups include alkanoyl groups (e.g., having from 1 to 6 carbon atoms in the alkyl group). Acetyl and pivaloyl are examples of acyl groups. Acyl groups may be substituted or unsubstituted.

A "carbamoyl" group is a group having the structure $\text{H}_2\text{N}-\text{CO}_2^-$. "Alkylcarbamoyl" and "dialkylcarbamoyl" refer to carbamoyl groups in which the nitrogen has one or two alkyl groups attached in place of the hydrogens, respectively. By analogy, "arylcarbamoyl" and "arylalkylcarbamoyl" groups include an aryl group in place of one of the hydrogens and, in the latter case, an alkyl group in place of the second hydrogen.

A "carboxyl" group is a -COOH group.

An "alkoxy" group is an alkyl-O- group in which "alkyl" is as previously described.

An "alkoxyalkyl" group is an alkyl group as previously described, with a hydrogen replaced by an alkoxy group, as previously described.

5 A "halogen" or "halo" group is fluorine, chlorine, bromine or iodine.

A "heterocyclyl" group is a 5 to about 10 membered ring structure, in which one or more of the atoms in the ring is an element other than carbon, e.g., N, O, S. A heterocyclyl group can be aromatic or non-aromatic, i.e., can be saturated, or can be partially or fully unsaturated. Examples of heterocyclyl groups include pyridyl, imidazolyl, furanyl, thienyl, thiazolyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, indolyl, indolinyl, isoindolinyl, piperidinyl, pyrimidinyl, piperazinyl, isoxazolyl, isoxazolidinyl, tetrazolyl, and benzimidazolyl.

A "substituted heterocyclyl" group is a heterocyclyl group wherein one or more hydrogens are replaced by substituents such as alkoxy, alkylamino, dialkylamino, carbalkoxy, carbamoyl, cyano, halo, trihalomethyl, hydroxy, carbonyl, thiocarbonyl, hydroxyalkyl or nitro.

15 A "hydroxyalkyl" means an alkyl group substituted by a hydroxy group.

A "sulfamoyl" group has the structure $-S(O)_2NH_2$. "Alkylsulfamoyl" and "dialkylsulfamoyl" refer to sulfamoyl groups in which the nitrogen has one or two alkyl groups attached in place of the hydrogens, respectively. By analogy, "arylsulfamoyl" and "arylalkylsulfamoyl" groups include an aryl group in place of one of the hydrogens and, in the latter case, an alkyl group in place of the second hydrogen.

20 An "antagonist" is a molecule that binds to a receptor without activating the receptor. It competes with the endogenous ligand for this binding site and, thus, reduces the ability of the endogenous ligand to stimulate the receptor.

25 In the context of the present invention, a "selective antagonist" is an antagonist that binds to a specific subtype of adenosine receptor with higher affinity than to other subtypes. The antagonists of the invention can, for example, have high affinity for A_1 receptors or for A_{2a} receptors and are selective, having (a) nanomolar binding affinity for one of these two subtypes and (b) at least 10 times, more preferably 50 times, and most preferably at least 100 times, greater affinity for one subtype than for the other.

The invention provides numerous advantages. The compounds are easily manufactured from readily available starting materials, in a relatively small number of steps. The compounds have a number of variable regions, allowing for systematic optimization. As A_1 -specific antagonists, the compounds have broad medicinal utility. Since the compounds are highly potent and specific A_1 antagonists, they can (1) be used in low doses to minimize the likelihood of side effects and (2) be incorporated into numerous dosage forms including, but not limited to, pills, tablets, capsules, aerosols, suppositories, liquid formulations for ingestion or injection, dietary supplements, or topical preparations. In addition to medical applications, the antagonist compound can be used in the treatment of livestock and pet animals.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a series of illustrations of adenosine A_1 antagonists.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

In general, the invention features highly potent and selective antagonists of the adenosine A_1 receptor. Selective antagonists of the adenosine A_{2A} receptor are also disclosed.

Synthesis of the Adenosine Antagonist Compounds

The compounds of the invention may be prepared by a number of known methods. In general, xanthines can be obtained by the reaction of 1,3-disubstituted-5,6-diaminouracils

with aldehydes or carboxylic acids or carboxylic acid chlorides, followed by ring closure. Alternatively, 1,3-disubstituted-6-amino-5-nitrosouracils can be condensed with aldehydes to afford the desired xanthines.

1,3-Disubstituted-5,6-diaminouracils can be prepared by treating the corresponding symmetrically or unsymmetrically substituted urea with cyanoacetic acid, followed by nitrosation and reduction (see, e.g., *J. Org. Chem.* **16**, 1879, 1951; *Can J. Chem.* **46**, 3413, 1968). Alternatively, unsymmetrically substituted xanthines can be accessed via the method of Mueller (*J. Med. Chem.* **36**, 3341, 1993). In this method, 6-aminouracil is monoalkylated specifically at N3 of the uracil under Vorbruggen conditions. Following nitrosation, reduction, reaction with an aldehyde or carboxylic acid or carboxylic acid chloride, alkylation at N1 of the uracil, and ring closure, xanthines result.

In a particular case, anti-3-oxo-tricyclo[2.2.1.0^{2,6}] heptan-3-carboxylic acid can be easily synthesized from norbornadine, paraformaldehyde, formic acid and sulfuric acid. (see, e.g., *J. Am. Chem. Soc.* **99**, 4111, 1977; *Tetrahedron* **37** Supplement No.1 411, 1981. It can be easily resolved using *Candida antarctica* Lipase A (*Tetrahedron Lett.* **37**, 3975, 1996).

In many cases, the desired aldehydes, ketones, carboxylic acids and carboxylic acid chlorides are commercially available (e.g., from Aldrich Chemical Co., Inc., Milwaukee, Wisc.) or readily prepared from commercially available materials by well-known synthetic methods. Such synthetic methods include, but are not limited to, oxidation, reduction, hydrolysis, alkylation and Wittig homologation reactions.

The bicycloalkane carboxylic acids of the invention can also be prepared by published methods (see, e.g., *Aust. J. Chem.* **38**, 1705, 1985; *Aust J. Chem.* **39**, 2061, 1986; *J. Am. Chem. Soc.* **75**, 637, 1953; *J. Am. Chem. Soc.* **86**, 5183, 1964; *J. Am. Chem. Soc.* **102**, 6862, 1980; *J. Org. Chem.* **46**, 4795, 1981; and *J. Org. Chem.* **60**, 6873, 1995).

Uses for the Adenosine Antagonist Compounds

Activation of adenosine receptors elicits many physiological responses, including reductions in renal blood flow, reductions in glomerular filtration rate, and increases in sodium reabsorption in kidney. Activation of adenosine receptors reduces heart rate, reduces conduction velocity, and reduces contractility. These, and the other effects of activation of adenosine receptors in other organs, are normal regulatory processes. However, these effects become pathological in many disease states. Thus, adenosine antagonists have extensive application in both prevention and treatment of disease. Diseases that can be prevented

and/or treated with adenosine receptor antagonists include any conditions (a) marked by the presence of an abnormal level of adenosine and/or (b) requiring for treatment the inhibition or stimulation of adenosine production and/or release. Such conditions include, but are not limited to, congestive heart failure, cardio-pulmonary resuscitation, hemorrhagic shock, and other cardiac and circulatory disorders; degenerative disorders of the central nervous system; respiratory disorders (e.g., bronchial asthma, allergic lung diseases); and many diseases for which diuretic treatment is indicated (e.g., acute and chronic renal failure, renal insufficiency, hypertension). Degenerative illnesses such as Parkinson's disease, depression, traumatic brain damage, post-stroke neurological deficit, neonatal brain trauma, dyslexia, hyperactivity, and cystic fibrosis have all been linked to adenosine receptor activity. Other conditions in which treatment with adenosine receptor antagonists can have therapeutic utility include cirrhotic ascites, neonatal apnea, renal failure associated with traditional diuretic therapy, diabetes, and asthma.

Additionally, applicants have discovered that the administration of highly selective and potent adenosine A₁ receptor antagonists, for example, can elicit a diuretic response when administered alone and can potentiate the diuretic response to traditional diuretics. In addition, administration of adenosine receptor antagonists with traditional diuretics attenuate the reduction of glomerular filtration rate induced by traditional diuretics. The claimed methods are applicable, for example, in edematous conditions, such as congestive heart failure and ascites.

Administration of the Adenosine Antagonist Compounds

The compounds can be administered to an animal (e.g., a mammal such as a human, non-human primate, horse, dog, cow, pig, sheep, goat, cat, mouse, rat, guinea pig, rabbit, hamster, gerbil, ferret, lizard, reptile, or bird). The compounds can be administered in any manner suitable for the administration of pharmaceutical compounds, including, but not limited to, pills, tablets, capsules, aerosols, suppositories, liquid formulations for ingestion or injection or for use as eye or ear drops, dietary supplements, and topical preparations. The compounds can be administered orally, intranasally, transdermally, intradermally, vaginally, intraaurally, intraocularly, buccally, rectally, transmucosally, or via inhalation, implantation (e.g., surgically), or intravenous administration.

Optionally, the compounds can be administered in conjunction with a non-adenosine modifying pharmaceutical composition (e.g., in combination with a non-adenosine modifying

diuretic as described, for example, in co-pending application PCT/US99/08879 filed April 23, 1999, incorporated herein by reference in its entirety).

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES

Example 1

8-(5-Oxo-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

Anti-3-oxotricyclo(2.2.1.0^{2,6})heptane-7-carboxylic acid (837 mg) was taken in CH₂Cl₂ (20 ml) at 0°C. Triethylamine (1.74 ml), isobutylchloroformate (724 µl) were added and stirred at 0°C for 15 min. 1,3-Dipropyl-5,6-diaminouracil HCl was added and stirred at 0°C for 30 min and at room temperature overnight. The next day, the reaction mixture was diluted with water (50 ml) and extracted with CH₂Cl₂ (3x25 ml). The combined organic layer was washed with sat NaHCO₃, water, brine, and dried over Na₂SO₄. Concentration of the solvent gave a crude product, which was taken to next step without further purification. Mass (ES⁺ 361).

5-Oxo-tricyclo[2.2.1.0^{2,6}]heptane-3-carboxylic acid (6-amino-2,4-dioxo-1,3-dipropyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-amide (360 mg) from step 1 was taken in 1:1 isopropanol:water (5 ml) and KOH (84 mg) was added. The reaction mixture was refluxed for one and half-hour. After cooling the reaction mixture to room temperature, iPrOH was removed by rotavap. The aqueous layer was neutralized with 2N HCl and extracted with ethyl acetate (3x50 ml). The combined organic layer was washed with water and brine and dried over Na₂SO₄. After concentration, the crude product was purified by silica gel chromatography, eluting with ethyl acetate:hexane (1:1). Yield (75 mg) Mass (ES⁺ 343).

Example 2

Endo/exo 8-(5-Hydroxy-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

8-(5-Oxo-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (700 mg) was dissolved in MeOH (50 ml). NaBH₄ (100 mg) was added at 0°C and stirred for 5 min. Water was added and stirred for 30 min. MeOH was removed by rotavap under reduced pressure. The reaction mixture was extracted with ethyl acetate, washed with water,

brine, and dried over MgSO_4 . Concentration gave 700 mg of a mixture of endo:exo alcohols in a 6:4 ratio.

Example 3

8-(5-Methylene-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

Methyl-triphenyl-phosphonium bromide (2.08 g) was taken in THF (50 ml) at -78°C . $n\text{BuLi}$ (3.66 ml, 1.6 M) was added slowly at -78°C and stirred for 1 hr. 8-(5-Oxo-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (Example 1) (1g) was dissolved in THF and added to the reaction mixture at -78°C slowly. After the addition was over, the reaction mixture was allowed to warm to room temperature slowly and stirred at room temperature overnight. The next day, the reaction mixture was quenched with 1N HCl and extracted with ethyl acetate (3x50 ml). The combined organic layer was washed with water, brine and dried over Na_2SO_4 . After concentration the product was purified by silica gel column. Mass (ES^+ 341).

Example 4

8-(5-Methoxymethylene-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

Methoxymethyl-triphenyl-phosphonium chloride (1.1 g) was taken in toluene (10 ml) at 0°C . Potassium bis(trimethylsilyl)amide (0.5 M in toluene, 12.8 ml) was added and stirred at 0°C for 1 hr. 8-(5-Oxo-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (Example 1) (1g) was added to the reaction mixture, which was then warmed to room temperature and stirred overnight. The next day, the reaction mixture was quenched with water, and extracted with ethyl acetate (3x50 ml). The combined organic layer was washed with water and brine, and dried over Na_2SO_4 . After concentration, the crude product (620 mg) was purified by column. Mass (ES^+ 371).

Example 5

8-(5-endo Hydroxy-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

Sodium borohydride (22 mg) was taken in MeOH (5 ml) at 0°C . 8-(5-Oxo-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (Example 1) (200

mg) in MeOH (5 ml) was added to reaction mixture at 0°C. After stirring at 0°C for 1 hr, the reaction mixture was quenched with 1N HCl and extracted with ethyl acetate (3X25 ml). The combined organic layer was washed with water, brine and dried over Na₂SO₄. After concentration of the solvent, the product was purified by preparative HPLC. Mass (ES⁺ 345)
Product is a mixture of two isomers ratio (2:1). The major isomer is the endo hydroxyl compound.

Example 6

8-(5-exo Hydroxy-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

To a solution of 8-(5-Oxo-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (Example 1) (2 g) in THF (40 ml) at -78°C was added dropwise a solution of K-selectride (20 ml, 1M in THF). The mixture was stirred at -78°C for 30 min, then allowed to warm to 0°C, quenched with water and extracted with ethyl acetate (3x50ml).
The combined organic layer was washed with brine and dried over MgSO₄. Filtered and concentrated under reduced pressure to give the desired product (1.97g) as a 20:1 mixture of exo and endo alcohols. Mass (ES⁺ 345).

Example 7

8-(5-endo-Hydroxymethyl-5-methyl-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione and 8-(5-exo-Hydroxy-5-hydroxymethyl-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

8-(5-Methoxymethylene-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (368 mg) was taken in THF (5 ml). 1N HCl (2 ml) was added to the reaction mixture and stirred at room temperature for 4 hrs. The reaction mixture was extracted with ethyl acetate (3x25 ml). The combined extract was washed with sat NaHCO₃, water, and brine, and dried over Na₂SO₄. The product was a mixture of endo and exo aldehydes, which was taken to next step without further purification.

The mixture of aldehydes was reduced using NaBH₄ in MeOH following the procedure of Example 5. The product mixture of endo and exo hydroxyl methyl compounds was separated by preparative HPLC. Mass (ES⁺ 359).

The following compounds were prepared by the same methods:

Example 7a: Endo-8-(5-endo-Hydroxymethyl-5-methyl-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

Example 7b: Endo-8-(5-endo Hydroxymethyl-5-methyl-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

Example 8

8-(5-Hydroxy-5-hydroxymethyl-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

8-(5-Methylene-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (284 mg) was taken in acetone:water (1:1, 5 ml) at 0°C. OsO₄ (2 ml) was added and the mixture was stirred for 15 min. N-Methylmorpholine-N-oxide (120 mg) was added and the mixture was stirred at room temperature overnight. The next day the reaction mixture was quenched with NaHSO₃ solution, extracted with ethyl acetate (3x25 ml). Combined organic layer was washed with water, brine and dried over Na₂SO₄. After concentration the crude product was purified on a silica column. (ES⁺ 375)

Example 9

Endo-5-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]heptane-3endo carboxylic acid

8-(5-endo Hydroxymethyl-5-methyl-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione and 8-(5-exo Hydroxy-5-hydroxymethyl-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (100 mg) was taken in DMF (5 ml). PDC (232 mg) was added at 0°C and stirred at 0°C to room temperature overnight. The next day, another 232 mg of PDC was added stirred at room temperature for 24 hrs. DMF was removed under reduced pressure. Dissolved in sat NaHCO₃ solution and extracted with ethyl acetate (2x50ml). Aqueous layer was acidified with 1N HCl and extracted with ethyl acetate (3 x100 ml). Ethyl acetate layer was washed with brine, dried over Na₂SO₄, and concentrated. Mixture of exo and endo acids was separated by preparative HPLC. Mass (ES⁺ 373).

The following compound was prepared by the same method:

Example 9a: Exo-5-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]heptane-3exo carboxylic acid

Example 10

[5-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]hept-3-ylidene]-acetic acid

Methyl diethyl phosphono acetate (100 μ l) was taken in toluene (5 ml) at 0°C. Potassium bis(trimethylsilyl)amide (0.5 M in toluene, 2.2 ml) was added and stirred at 0°C for 1 hr. 8-(5-Oxo-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (Example 1) (171 mg) dissolved in 5ml of toluene was added to the reaction mixture and warmed to room temperature and stirred overnight. The next day, the reaction mixture was quenched with water, acidified with 1N HCl, extracted with ethyl acetate (2x100 ml). The combined organic layer was washed with water, brine and dried over Na₂SO₄. After concentration the crude product (156 mg) was taken to next step without further purification. Mass (ES⁺ 399).

The ester (156 mg) from step 1 was hydrolyzed using LiOH (34 mg). The product was purified by preparative HPLC. Yield (52 mg). Mass (ES⁺ 385).

Example 11

[5-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]hept-3-yl]-acetic acid

The product (100 mg) from step 1 of Example 10 was hydrogenated in EtOH (5 ml) using Pd/C 5% at 60 psi of H₂ for 24 hrs. Catalyst was filtered and the solvent was concentrated. The product was taken to the next step.

The ester (90 mg) from step 1 was hydrolyzed with LiOH (19 mg) in MeOH:H₂O (5:1, 5 ml) at room temperature overnight. The product was purified by preparative HPLC. Yield: 51 mg. Mass (ES⁺ 387).

Example 12**8-(2-Oxo-bicyclo[2.2.1]hept-7-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione**

2-Oxo-bicyclo[2.2.1]heptane-7-carboxylic acid (308 mg) was couple to 1,3-Dipropyl-5,6-diaminouracil.HCl (576 mg) and cyclized using the procedures from Example 1. Yield: 320 mg. Mass (ES⁺ 345).

Example 13**8-(2-Hydroxy-bicyclo[2.2.1]hept-7-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione**

8-(2-Oxo-bicyclo[2.2.1]hept-7-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (200 mg) was reduced using NaBH₄ (44 mg) in MeOH (10 ml). Yield 120 mg. Mass (ES⁺ 347).

Example 14**5-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-3-hydroxymethyl-tricyclo[2.2.1.0^{2,6}]heptane-3-carboxylic acid**

Anti-3-oxotricyclo(2.2.1.0^{2,6})heptane-7-carboxylic acid (2.0 g) was taken in MeOH (50 ml) and conc. H₂SO₄ (0.2 ml) was added and refluxed overnight. The next day, after cooling the reaction mixture was poured into sat NaHCO₃ solution and extracted with ethyl acetate. Concentration of ethyl acetate gave 2.61 g of 5,5-Dimethoxy-tricyclo[2.2.1.0^{2,6}]heptane-3-carboxylic acid methyl ester.

5,5-Dimethoxy-tricyclo[2.2.1.0^{2,6}]heptane-3-carboxylic acid methyl ester (1.01 g) from step 1 was taken in dry THF (20 ml) at -78°C and LDA (3.53 ml, 2M in THF) was added dropwise. The mixture was at -78°C for 1 hr. Next BOMCl (2.29 g) was added dropwise. After 30 min at -78°C the mixture was warmed to 0°C and stirred for 1 hr. The reaction was quenched with sat NH₄Cl and extracted with ethyl acetate (2x50 ml). After concentration the crude product was take-up in THF (20 ml) and 1N HCl (5 ml) was added. The reaction mixture was stirred at room temperature for 1 hr, dilute with water extracted with ethyl acetate. Ethyl acetate was washed with brine and dried over MgSO₄. After concentration the product was purified on a silica column. Yield 515 mg.

Step 3: 3-Benzyloxymethyl-5-oxo-tricyclo[2.2.1.0^{2,6}]heptane-3-carboxylic acid methyl ester from step 2 was converted to 3-Benzyloxymethyl-5-formyl-tricyclo[2.2.1.0^{2,6}]heptane-3-carboxylic acid methyl ester following the procedures from Example 4 and Example 7.

Into a solution of 3-benzyloxymethyl-5-formyl-tricyclo[2.2.1.0^{2,6}]heptane-3-carboxylic acid methyl ester (475 mg) in 10ml of t-BuOH and 8 ml of 2-methyl-but-2-ene at 0°C was added NaClO₂ (904 mg) and NaH₂PO₄ H₂O (1.37 g) in water (5 ml). The mixture was stirred at room temperature for 5 hrs. The reaction was acidified with HOAc and extracted with ethyl acetate, washed with water and dried. Concentration gave the desired acid (175 mg).

3-Benzyloxymethyl-tricyclo[2.2.1.0^{2,6}]heptane-3,5-dicarboxylic acid 3-methyl ester (168 mg) from above was coupled to 1,3 dipropyl-5,6-diaminouracil•HCl (263 mg) using EDC (191 mg), DIEA (258 mg) in CH₂Cl₂ (20 ml) at room temperature overnight. After workup the product was cyclized using aq. KOH in iPrOH.

3-Benzyloxymethyl-5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]heptane-3-carboxylic acid (50 mg) was hydrogenated in ethyl acetate using Pd/C 5% under 1 atm of H₂ overnight. The catalyst was filtered through silica eluting with 10% MeOH:CHCl₃. Yield 31 mg. Mass (ES⁺ 403).

Example 15

[7-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[2.2.1]hept-2-ylidene]-acetic acid

8-(2-Oxo-bicyclo[2.2.1]hept-7-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione was converted to the title compound using the procedure from Example 10. Mass (ES⁺ 387).

Example 16

Endo 2-tert-Butoxycarbonylamino-3-methyl-butyric acid 5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]hept-3-yl ester

To a solution of DIC (126 mg), and DMAP (122 mg) in CH₂Cl₂ (10 ml) at 0°C was added Boc-L-Valine (217 mg). The mixture was stirred for 30 min and then 8-(5-endo hydroxy-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (110 mg) was added. The resulting mixture was stirred at room temperature overnight. The next day, the reaction was diluted with ethyl acetate, washed with in HCl, sat NaHCO₃, and brine, and dried over MgSO₄. The product was filtered, concentrated, and purified on silica to give the desired compound. Yield 155 mg Mass (ES⁺ 544).

Example 16a: Exo-2-tert-Butoxycarbonylamino-3-methyl-butyrac acid 5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]hept-3-yl ester.

Example 17

5 **Endo -2-Amino-3-methyl-butyrac acid 5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]hept-3-yl ester HCl**

Endo 2-tert-Butoxycarbonylamino-3-methyl-butyrac acid 5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]hept-3-yl ester (120 mg) was taken in THF (2 ml). 1M HCl in ether (2 ml) was added and the reaction mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure. The crude residue was taken up in THF, the product was precipitated by adding ether. Yield 55 mg. Mass (ES⁺ 444).

Example 18

15 **(+) Endo 8-(5-Hydroxy-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione**

(+)Anti-3-oxotricyclo(2.2.1.0^{2,6})heptane-7-carboxylic acid, prepared using the procedure described in *Tetrahedron Letters*, 37:3975-3976, 1996, was coupled to 1,3-dipropyl-5,6-diaminouracil and cyclized following the procedure described in Example 1.

20 The resulting ketone was reduced to an alcohol using the procedure from Example 5.

Example 18a: (-) Endo Endo 8-(5-Hydroxy-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

Example 19

25 **Exo 2-Amino-3-methyl-butyrac acid 5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]hept-3-yl ester; compound with trifluoro-acetic acid**

Exo-2-tert-Butoxycarbonylamino-3-methyl-butyrac acid 5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]hept-3-yl ester (100 mg) was treated with CH₂Cl₂:TFA (1:1, 5ml) at room temperature overnight. The solvent was removed under reduced pressure and the crude residue was purified by HPLC. Mass (ES⁺ 444).

Example 20**Endo-[5-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]hept-3-yloxy]-acetic acid**

8-(5-Oxo-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (1g) was taken in DMF (10 ml) Cs₂CO₃ (5.85 g) was added followed by BOMCl (810 µl) at room temperature. The reaction mixture was stirred at room temperature overnight. Cs₂CO₃ was filtered off, and the DMF was removed under reduced pressure. The crude product was purified on silica column.

The resulting ketone was reduced using NaBH₄ following the example. Yield (1.3 g) mixture of endo and exo alcohols.

NaH (240 mg, 60% suspension in mineral oil) was washed with dry pentane 3 times and taken in dry THF at 0°C. Mixture of alcohols from above (500 mg) in THF (5 ml) was added to the reaction and stirred at 0°C for 1hr. Bromo-t-butylacetate (420 mg) was added at 0°C and stirred at 0°C to room temperature overnight. The next day, the reaction mixture was heated at 60°C for 3 hr. After cooling to room temperature, the reaction mixture was diluted with water, extracted with ethyl acetate (3x50ml). The combined ethyl acetate layer was washed with water, brine and dried over Na₂SO₄. After concentration the crude mixture was taken to next step.

Product from above was taken in ethyl acetate (5 ml) and 100 mg of Pd/C 10 %, 1 ml of conc. HCl was added. The reaction mixture was hydrogenated under 60 psi H₂ overnight. The catalyst was filtered off and the solvent was removed by rotavap. The residue was taken in 5ml of MeOH and LiOH (100 mg) was added. The reaction mixture was stirred at room temperature overnight. The next day, the solvent was removed, diluted with water, extracted with ethyl acetate (2x50ml). The aqueous layer was acidified with 1N HCl, extracted with ethyl acetate (3x50ml). Ethyl acetate layer was washed with water and brine, and dried over Na₂SO₄. Concentration of the ethyl acetate layer gave 390 mg mixture of endo and exo products that was separated by HPLC. Mass (ES⁺ 403).

Example 20a: Exo-[5-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]hept-3-yloxy]-acetic acid

Example 21

(-) Endo-2-tert-Butoxycarbonylamino-3-methyl-butyric acid 5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]hept-3-yl ester

(-)Endo 8-(5-Hydroxy-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione was coupled to Boc-L-Valine using the procedure from Example 16.

Example 22

(-) Endo 2-Amino-3-methyl-butyric acid 5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]hept-3-yl ester HCl

(-) Endo-2-tert-Butoxycarbonylamino-3-methyl-butyric acid 5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-tricyclo[2.2.1.0^{2,6}]hept-3-yl ester was converted to the product following the procedure from example Example 17.

Mass (ES⁺ 444).

Example 23

8-[5-(3-Dimethylamino-propylidene)-tricyclo[2.2.1.0^{2,6}]hept-3-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; compound with trifluoro-acetic acid

(3-Dimethylamino-propyl)-triphenyl-phosphonium; bromide (514 mg) was taken in THF (20 ml) at 0°C. Potassium bis(trimethylsilyl)amide (0.5 M in toluene, 5 ml) was added and stirred at 0°C for 1 hr. 8-(5-Oxo-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (342 mg) dissolved in 5 ml of THF was added to the reaction mixture at 0°C. The reaction mixture was stirred at 0°C to room temperature overnight. The next day, the THF was removed by rotavap under reduced pressure, the residue was dissolved in water (10 ml), acidified with 1N HCl, and extracted with ethyl acetate (2x100ml). The aqueous layer was concentrated and purified by HPLC. Yield 140 mg. Mass (ES⁺ 412).

Example 24

8-[5-(3-Dimethylamino-propyl)-tricyclo[2.2.1.0^{2,6}]hept-3-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

8-[5-(3-Dimethylamino-propylidene)-tricyclo[2.2.1.0^{2,6}]hept-3-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; compound with trifluoro-acetic acid was hydrogenated under 60 psi using Pt /C 5 % in EtOH (10 ml) and 1 ml conc. HCl overnight. Catalyst was filtered and

solvent was removed under reduced pressure. Crude product was purified by HPLC Yield 30 mg. Mass (ES^+ 414).

Example 25

8-(4-Hydroxy-bicyclo[3.2.1]oct-6-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

4-Acetoxy-bicyclo[3.2.1]octane-6-carboxylic acid (425 mg) was taken in CH_2Cl_2 (5 ml) at $0^\circ C$. TEA (700 μl) and i-butylchloroformate (285 μl) were added and stirred at $0^\circ C$ for 30 min. 1,3-Dipropyl-5,6-diaminouracil.HCl (524 mg) was added and stirred at $0^\circ C$ for 30 min and at room temperature overnight. The next day, the reaction was diluted with CH_2Cl_2 (25 ml), washed with water, dried over Na_2SO_4 , and concentrated. The crude product (820mg) was taken to next step without further purification.

The product was cyclized in i-PrOH/water (1:1, 15 ml) using KOH (280 mg) under reflux for 1 hr. Followed the procedure from Example 1. Yield 450 mg. Mass (ES^+ 361).

Example 26

8-(4-Oxo-bicyclo[3.2.1]oct-6-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

8-(4-Hydroxy-bicyclo[3.2.1]oct-6-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (140 mg) from step 1 was taken in CH_2Cl_2 (5ml). Celite (2 g) was added, followed by PCC (90 mg) and stirred at room temperature for 1 hr. Additional PCC (90 mg) was added and stirred for 2 hrs at room temperature. The reaction mixture was diluted with ether (100 ml) and filtered through celite and concentrated. Purified on silica column eluted with ethyl acetate: hexane (25:75) to yield 65 mg of the desired product. Mass (ES^+ 369).

Example 27

8-(4-Hydroxy-4-methyl-bicyclo[3.2.1]oct-6-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

8-(4-Oxo-bicyclo[3.2.1]oct-6-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (51 mg) was taken in THF (3 ml) at $0^\circ C$. CH_3MgBr (1 ml, 3.0 M) was added and stirred for 2 hrs. The reaction was quenched with sat. NH_4Cl , and extracted with ethyl acetate. The organic layer was washed with water, brine, and dried over Na_2SO_4 . Concentration followed by purification on silica column gave the desired product. Mass (ES^+ 375).

Example 28**8-(3-Oxo-2-aza-bicyclo[3.2.1]oct-7-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione**

8-Bicyclo[2.2.1]hept-5-en-2-yl-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (5 g) was treated with NaH (878 mg) in THF at 0°C. After one hour, BOMCl (2.52 ml) was added dropwise and stirred overnight. The next day, the reaction was quenched with water, extracted with ethyl acetate, washed with water and dried over Na₂SO₄. After concentration, the crude product was taken to next step.

7-Benzyloxymethyl-8-bicyclo[2.2.1]hept-5-en-2-yl-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (5 g) from step 1 was taken in THF(25 ml) at 0°C. BH₃THF (12 ml, 1M) was added. After two hours, 6N NaOH (1 ml) and H₂O₂ (12 ml) were added and stirred for another 2 hrs. The reaction mixture was acidified with 1N HCl and extracted with ethyl acetate. The organic layer was washed with water, brine and dried over Na₂SO₄. Concentration of the organic layer gave a mixture of two products, which were separated by column chromatography. The less polar compound, 7-benzyloxymethyl-8-(6-hydroxy-bicyclo[2.2.1]hept-2-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione, (major product) yield 1.7 g. Mass (ES+ 467).

7-Benzyloxymethyl-8-(6-hydroxy-bicyclo[2.2.1]hept-2-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (1.6 g) was oxidized using PCC (855 mg) following the procedure from Example 26.

7-Benzyloxymethyl-8-(6-oxo-bicyclo[2.2.1]hept-2-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (435 mg) from step 3 was taken in acetic acid (5 ml). Hydroxylamino-O-sulfonic acid (211 mg) was added and refluxed for 3 hrs. After cooling, the reaction mixture was extracted with ethyl acetate (3x25ml). The organic layer was washed with sat. NaHCO₃, water, brine and dried over Na₂SO₄. Solvent was removed by rotavap and the desired product was purified on a silica column. Mass (ES⁺ 360).

Example 29**8-(2-Oxo-3-aza-bicyclo[3.2.1]oct-8-yl)-1,3-dipropyl-3,9-dihydro-purine-2,6-dione**

Into a solution of NaN₃ (65 mg) in CHCl₃ (2 ml) was added H₂SO₄ (0.5ml). The resulting solution was cooled to 0°C. 8-(2-Oxo-bicyclo[2.2.1]hept-7-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (173 mg) in CHCl₃ (3ml) was added. The resulting solution was stirred at room temperature for 3 hrs. The reaction mixture was poured over ice and

neutralized with NaHCO₃, extracted with ethyl acetate (3x25 ml). The combined extract was dried over MgSO₄, filtered, and concentrated. The crude product was purified by recrystallization from MeOH. Yield 155 mg. Mass (ES⁺ 360).

5

Example 30

[8-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-3-aza-bicyclo[3.2.1]oct-3-yl]-acetic acid benzyl ester

8-(2-Oxo-3-aza-bicyclo[3.2.1]oct-8-yl)-1,3-dipropyl-3,9-dihydro-purine-2,6-dione (85 mg) was taken in THF (2ml) and 1 ml of 1M LAH in ether was added and refluxed overnight. The next day, after cooling the reaction was quenched with ice, 1N KOH was added, extracted with ethyl acetate (3 x25 ml). Combined extract was washed with brine and dried over MgSO₄. The solvent was removed under reduced pressure. The product (14 mg) was taken in 2 ml of CH₂Cl₂, Bromoacetic acid benzyl ester (23 mg) was added and stirred at room temperature overnight. The next day, the reaction mixture was basified with 1N NaOH, extracted with ethyl acetate. The crude product was purified on a silica column. Yield (7 mg) Mass (ES⁺ 494).

10

15

Example 31

8-(3-Oxo-2-aza-bicyclo[3.2.1]oct-8-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

8-(2-Oxo-bicyclo[2.2.1]hept-7-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (278 mg) was converted to the product (185 mg) following the procedure from Example 27. Mass (ES⁺ 360).

20

Example 32

8-(3-Oxo-4-aza-tricyclo[3.2.1.0^{2,7}]oct-6-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

8-(5-Oxo-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (150 mg) was converted to the product (135 mg) following the procedure from Example 27. Mass (ES⁺ 358).

25

Example 33**8-(3-Oxo-bicyclo[3.2.1]oct-8-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione**

3-Oxo-bicyclo[3.2.1]octane-8-carboxylic acid ethyl ester, prepared using the lit procedure (*J. Org. Chem.* 1997, 62, 174-181), was hydrolyzed to the keto acid using KOH in MeOH.

3-Oxo-bicyclo[3.2.1]octane-8-carboxylic acid (205 mg) from step 1 was coupled to diaminouracil HCl (395 mg) using EDC (287 mg) in CH₂Cl₂ in the presence of DIEA (490 mg) and cyclized in iPrOH (50 ml), 1N KOH (10 ml) at reflux overnight. The crude product was purified on silica column. Yield (210 mg). Mass (ES⁺ 359).

Example 34**Exo 8-(3-Hydroxy-bicyclo[3.2.1]oct-8-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione**

8-(3-Oxo-bicyclo[3.2.1]oct-8-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (30 mg) was dissolved in MeOH (2ml) and NaBH₄ (20 mg) was added to the reaction at 0°C and stirred for 10 min. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was dried over MgSO₄ and concentrated. The crude products (mixture of endo and exo alcohols) were purified by HPLC. Exo alcohol 4mg. Mass (ES⁺ 361)
Example 34a: Endo 8-(3-Hydroxy-bicyclo[3.2.1]oct-8-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione. Endo alcohol (12 mg). Mass (ES⁺ 361).

Example 35**3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-2-ene-8-carboxylic acid**

Into a solution of 3-Oxo-bicyclo[3.2.1]octane-8-carboxylic acid ethyl ester (100 mg), prepared using the procedure of *J. Org. Chem.* 62:174-181, 1997, in THF (5 ml) at -78°C, was added dropwise a solution of LDA (0.3 ml, 2M). The reaction mixture was stirred at -78°C for 30 min. The resulting enolate was quenched with Bis(trifluoromethylsulfonyl)-amino benzene (214 mg). After another 30 min at -78°C, the reaction mixture was quenched with sat. NH₄Cl. The reaction mixture was taken in ethyl acetate, washed with water, brine, and dried over MgSO₄. The solvent was removed under reduced pressure, the crude product was taken to next step without further purification.

The product from step 1 was taken in DMF (10 ml). 1,3-Dipropyl-5,6-diaminouracil.HCl (263 mg), PPh₃ (15 mg), Pd(OAc)₂ (7 mg), DIEA (194 mg) were added. The reaction mixture was stirred at 100°C under a slow bubbling of carbon monoxide for 1 day. The solution was cooled to room temperature, diluted with ethyl acetate, washed with 1N HCl, brine, and dried over MgSO₄. The solvent was removed under reduced pressure, the crude product was taken to next step without further purification.

The product from step 2 was cyclized in iPrOH (15 ml), 1N KOH (5 ml) under reflux overnight. After cooling to room temperature, the solvent was concentrated under reduced pressure, acidified with 1N HCl, saturated with solid NaCl, extracted with ethyl acetate, washed with brine and dried over MgSO₄. After concentration, the crude product was purified on silica column. Yield (50mg). Mass (ES⁺ 387).

Example 35a 3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylic acid ethyl ester. Mass (ES⁺ 416).

Example 36

3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]octane-8-carboxylic acid

3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-2-ene-8-carboxylic acid (Example 29) was hydrogenated using Pd/C in ethyl acetate. Mass (ES⁺ 389).

Example 37

8-(8-Oxo-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

The product (390 mg) from Example 35, was taken in THF (10 ml) 6N HCl (3 ml) and heated to reflux overnight. The next day,, after cooling to room temperature, poured over ice, neutralized with NaHCO₃, extracted with ethyl acetate, washed with brine and dried over MgSO₄. Filtered, concentrated, and purified on silica. Yield (321 mg). Mass (ES⁺ 359).

Example 38**8-(8-Hydroxy-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione**

8-(8-Oxo-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (25 mg) was reduced using NaBH₄ (30 mg) in MeOH at 0°C. The product was purified by HPLC. Yield (7 mg). Mass (ES⁺ 361).

Example 39**2-[3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-yl]-malonic acid**

8-(8-Hydroxy-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (30 mg) taken in CHCl₃ (5ml). To this solution Meldrum's acid (58 mg), piperidine (10 mg) were added and heated to reflux overnight. The next day,, after cooling to room temperature, diluted with ethyl acetate, washed with 1N HCl, sat NaHCO₃, brine, and dried. The solvent was removed under reduced pressure, the crude residue was taken up in MeOH, cooled to 0°C, NaBH₄ (30 mg) was added, the mixture was stirred for 15 min. The reaction was diluted with 1N HCl, extracted with ethyl acetate. The organic layer was washed with brine, dried over MgSO₄, and concentrated. The residue was taken up in THF (5ml) and 4N HCl (5 ml) was added and stirred for 1 day. The reaction mixture was extracted with ethyl acetate, washed with brine, and concentrated. The crude product was purified by HPLC. Yield (6 mg). Mass (ES⁺ 447).

Example 40**8-[3-(2-Dimethylamino-ethylamino)-bicyclo[3.2.1]oct-8-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; compound with trifluoro-acetic acid**

To a solution of 8-(3-Oxo-bicyclo[3.2.1]oct-8-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (60 mg) in CH₂Cl₂ (10 ml) at 0°C were added N1,N1-Dimethyl-ethane-1,2-diamine (100 mg), Na(OAc)₃BH (100 mg), and HOAc (5 drops). The reaction mixture was stirred room temperature overnight. The next day, the reaction was quenched with water, acidified with 1N HCl. The aqueous layer was washed with CH₂Cl₂, then neutralized with 1N KOH, extracted with ethyl acetate (3 x25 ml), washed with brine, dried over MgSO₄, and concentrated. The crude residue was purified by Preparative HPLC. Yield (31 mg) Mass (ES⁺ 431).

Example 40a: [3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-ylamino]-acetic acid ethyl ester. Mass (ES⁺ 446)

Example 40b: 8-[8-(2-Dimethylamino-ethylamino)-bicyclo[3.2.1]oct-3-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; compound with trifluoroacetic acid 8-(8-Oxo-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione. Mass (ES⁺ 431)

Example 40c: 1-[3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-yl]-pyrrolidine-2-carboxylic acid methyl ester; compound with trifluoroacetic acid. Mass (ES⁺ 472)

Example 40d: 8-(8-Morpholin-4-yl-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; compound with trifluoro-acetic acid. Mass (ES⁺ 430)

Example 40e: 8-(8-Allylamino-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; compound with trifluoro-acetic acid. Mass (ES⁺ 400)

Example 40f: 8-[8-(2-Piperidin-1-yl-ethylamino)-bicyclo[3.2.1]oct-3-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; compound with trifluoro-acetic acid. Mass (ES⁺ 471)

Example 40g: 8-[8-(2-Morpholin-4-yl-ethylamino)-bicyclo[3.2.1]oct-3-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; compound with trifluoro-acetic acid. Mass (ES⁺ 473)

Example 40h: N-{2-[3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-ylamino]-ethyl}-acetamide; compound with trifluoro-acetic acid. Mass (ES⁺ 445)

Example 40i: 8-[8-(3-Dimethylamino-propylamino)-bicyclo[3.2.1]oct-3-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; compound with trifluoro-acetic acid. Mass (ES⁺ 445)

Example 40j: 8-[8-(3-Morpholin-4-yl-propylamino)-bicyclo[3.2.1]oct-3-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; compound with trifluoro-acetic acid. Mass (ES⁺ 487)

Example 40k: 8-[8-(3-Imidazol-1-yl-propylamino)-bicyclo[3.2.1]oct-3-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; compound with trifluoro-acetic acid. Mass (ES⁺ 468)

Example 40l: 8-{8-[3-(2-Oxo-pyrrolidin-1-yl)-propylamino]-bicyclo[3.2.1]oct-3-yl}-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; compound with trifluoro-acetic acid. Mass (ES⁺ 468)

Example 41**8-(8-(1, 4-dioxa-spiro 4-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione**

Into a solution of 1-cyclopent-1-enyl-pyrrolidine (1.01g), triethylamine (0.82g), in CH₃CN (20 ml) was added a solution of 3-bromo-2-bromomethyl-propionic acid ethyl ester (2.03 g) in CH₃CN (10 ml). The reaction mixture was then heated to reflux overnight, cooled to room temperature, 5%HOAc (5 ml) was added then heated to reflux for 30 min. Cooled to room temperature diluted with ethyl acetate, washed with 1N HCl, sat NaHCO₃, brine, then dried. The solvent was removed under reduced pressure, the crude was taken up in ethylene glycol (30 ml), TsOH (50 mg) was added, the mixture was heated to reflux 1 day. Cooled to room temperature, diluted with ethyl acetate, washed with water, brine, and dried. After concentration the crude product was purified on silica to give 1.90g.

The product from step 1 was taken in THF (30 ml), MeOH (30 ml), 1N KOH (30 ml) and heated at 50°C overnight. The next day, cooled to room temperature, concentrated, acidified with 1N HCl, saturated with solid NaCl, extracted with ethyl acetate, washed with brine, concentrated.

The product from step 2 (Ketal acid) was coupled to diamino uracil HCl using EDC, DIEA in methylene chloride and cyclized using KOH in I-PrOH water.
Mass(ES⁺ 403)

Example 42**[3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-ylamino]-acetic acid**

[3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-ylamino]-acetic acid ethyl ester (Example 40a) was hydrolyzed using 1N KOH in MeOH/THF. Mass (ES⁺ 418)

Example 43**Exo-3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid ethyl ester**

3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-8-aza-bicyclo[3.2.1]oct-2-ene-8-carboxylic acid ethyl ester was hydrogenated using 10% Pd/C in MeOH. 1:3

mixture of endo and exo products was formed. The products were separated by HPLC. Exo isomer. Mass (ES^+ 418).

Example 43a: Endo-3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid ethyl ester.

5

Example 44

**Endo-8-(8-Aza-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione;
compound with trifluoro-acetic acid**

10

A mixture of Exo-3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid ethyl ester and Endo-3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid ethyl ester (1:3) was taken in 10 ml of CH_2Cl_2 . TMSI (1 ml) was added and stirred at room temperature for 48 hrs. MeOH (3 ml) was added and taken up in ethyl acetate, washed with sat $NaHCO_3$, washed with 10% solution of $Na_2S_2O_3$, brine, and dried over $MgSO_4$. Filtered and concentrated. Purified by HPLC Endo isomer. Mass (ES^+ 346).

15

Example 44a: Exo-8-(8-Aza-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; compound with trifluoro-acetic acid. Exo isomer Mass (ES^+ 346).

Example 45

20

1-[3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-yl]-pyrrolidine-2-carboxylic acid; compound with trifluoro-acetic acid

1-[3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-yl]-pyrrolidine-2-carboxylic acid methyl ester (Example 40c) was hydrolyzed with 1 N KOH in THF. Mass (ES^+ 458)

25

Example 46

**8-(8-Amino-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione;
compound with trifluoro-acetic acid**

30

8-(8-Allylamino-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione was hydrogenated in MeOH/HOAc in presence of Pd/C under 60 psi of H_2 for 8 hrs. Catalyst was filtered and concentrated. The crude product (mixture of two compounds) was purified by HPLC.

Example 46a: 1,3-Dipropyl-8-(8-propylamino-bicyclo[3.2.1]oct-3-yl)-3,7-dihydro-purine-2,6-dione; compound with trifluoro-acetic acid. Mass (ES^+ 402).

Example 47

5 [3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-yl]-acetic acid

2-[3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-yl]-malonic acid was converted to the product by refluxing in MeOH in the presence of 1N KOH (1 ml) for 2 days. Mass (ES^+ 403).

Example 48

8-(8-Hydroxy-8-methyl-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

15 *Trans* 8-Oxo-bicyclo[3.2.1]octane-3-carboxylic acid ethyl ester was synthesized followed the procedural written in J. Org. Chem. 1969, Vol. 34, page 1225-1229.

The above ketone (6.55g, 33 mmol), toluenesulfonic acid monohydrate (0.63g, 3 mmol), and ethylene glycol (20 ml) in toluene (100 ml) were refluxed using a Dean-Stark trap for the azeotropic elimination of water. After 8 h, the mixture was cooled down and washed with sodium bicarbonate, dried over magnesium sulfate, and concentrated down to get the correspondent ketal as *trans* isomer (7.26 g crude).

20 The above *trans*-ketal was treated with 1N NaOH in methanol at 50°C overnight. Methanol was evaporated off under vacuum, acidified with 2N HCl (ice cold), and extracted with ethyl acetate. Ethyl acetate was evaporated off to get 6.42 g *cis*- 8-Oxo-bicyclo[3.2.1]octane-3-carboxylic acid with the carbonyl group protected as Ketal form.

25 The above *cis*-acid (6.42 g, 30 mmol), 5,6-Diamino-1,3-dipropyl-1H-pyrimidine-2,4-dione, hydrochloride salt (10.34 g, 39 mmol), 5,6-Diamino-1,3-dipropyl-1H-pyrimidine-2,4-dione (7.51 g, 39 mmol), and diethyl isopropylamine (14 ml, 80 mmol) in methylene chloride (200 ml) were stirred at room temperature overnight. The mixture was then washed with 1N HCl, sodium bicarbonate, and brine, and dried over magnesium sulfate, and concentrated down under vacuo. The residue was refluxed in 1N NaOH/isopropanol overnight. The mixture was cooled down, acidified with 3N HCl, extracted with ethyl acetate, and concentrated down. The residue was then treated with 6N HCl/THF at 75°C for

3 h to get *cis* 8-(8-Oxo-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione as crude. Purification by column chromatography resulted in 4.5 grams of product (yield 40%).

The above ketone (40 mg, 0.11 mmol) was dissolved in THF (7 ml).

Methylmagnesium bromide (0.4 ml, 1N in THF) was added to the solution. The reaction mixture was stirred at room temperature for 2 h. The reaction was then quenched with NH₄Cl solution. Column purification resulted in 25 mg title compound (yield 60%). MS (M+1 375).

Example 49

Trans-3-[3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-yl]-propionic acid

(Methoxymethyl) triphenylphosphonium chloride (296 mg 0.86 mmol) in toluene was cooled in an ice-bath. Potassium bis (trimethylsilyl) amide (2.5 ml, 0.5M in toluene) was added dropwise through a syringe. The mixture was stirred at 0°C for 1 h. 8-(8-Oxo-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (100 mg) was then added to the mixture, and the mixture was allowed to warm to room temperature and was stirred overnight. Toluene was evaporated off, and the residue was treated with 1N HCl in THF at 70°C for 3 h. Ethyl acetate was used to extract the product. Column chromatography gave 94 mg of 3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]octane-8-carbaldehyde as a mixture of *cis* and *trans* yield (90%)

The above-obtained aldehyde (300 mg, 0.80mmol) in THF (10 ml) was reacted with (triphenyl-15-phosphanylidene)-acetic acid methyl ester (540 mg, 1.6 mmol), and the mixture was refluxed for 16 h. Solvent was then evaporated off, Purification by column chromatography resulted in 300 mg of 3-[3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-yl]-acrylic acid methyl ester as a mixture of *cis* and *trans* (Yield 70%).

After hydrogenation in Methanol using 10% Pd/C at 40 psi for 4 h got 3-[3-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-yl]-propionic acid methyl ester.

The above methyl ester was hydrolyzed in 1N NaOH/methanol at 60°C for 30 minutes. Preparative HPLC followed by work up resulted in 19 mg title compound as *trans* isomer. MS (M+1 417).

Example 43a *Cis*-3-[3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-yl]-propionic acid The *cis* isomer (5 mg) obtained from the above experiment was the title compound. MS (M+1 417).

Example 50

Trans-3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]octane-8-carboxylic acid

3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]octane-8-carbaldehyde (94 mg, 0.25 mmol) and 2-methyl-2-butene (2.5 ml, 2.5 mmol) in *tert*-butanol was stirred at ice-bath. Sodium dihydrogen phosphate monohydrate (348 mg, 2.5 mmol) and sodium chlorite (285 mg, 2.5 mmol) in water was added dropwise. The mixture was gradually brought to room temperature, and was continuously stirred overnight. Ethyl acetate was used to extract the product. Purification from column chromatography resulted in 20 mg title compound as the *trans* isomer. MS (M+1 389)

Example 51

Phosphoric acid mono-[3-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-yl] ester

Followed the procedure for making phosphoric acid mono-[4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[2.2.2]oct-1-yl] ester (in copending application), the title compound was made by using 8-(8-Hydroxy-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione as starting material. Overall yield 70%. MS (M+1 441)

Example 52

{2-[3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-ylamino]-ethyl}-carbamic acid tert-butyl ester; compound with trifluoro-acetic acid

Cis 8-(8-Oxo-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (50 mg, 0.12 mmol), (2-Amino-ethyl)-carbamic acid tert-butyl ester (35 mg, 0.2 mmol), and acetic acid (2 drops) in CH₂Cl₂/MeOH were stirred for 30 minutes. Sodium cyanoborohydride (0.5 ml, 1N in THF) was added to the mixture. The reaction mixture was stirred overnight.

The mixture was washed by sodium bicarbonate and brine, and was concentrated down under vacuo. After Prep. HPLC got 10 mg of product as TFA salt. MS (M+1 503).

The following compounds were made in an analogous fashion:

5 Example 52a: 1,3-Dipropyl-8-{8-[(thiophen-2-ylmethyl)-amino]-bicyclo[3.2.1]oct-3-yl}-3,7-dihydro-purine-2,6-dione; compound with trifluoro-acetic acid. MS (M+1 456)

Example 52b: 5-Dimethylamino-naphthalene-1-sulfonic acid {2-[3-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-ylamino]-ethyl}-amide; compound with trifluoro-acetic acid.. MS (M+1 636)

10 Example 52c: 8-{8-[2-(1H-Indol-3-yl)-ethylamino]-bicyclo[3.2.1]oct-3-yl}-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; compound with trifluoro-acetic acid. MS (M+1 503)

Example 52d: 8-{8-[2-(5-Nitro-pyridin-2-ylamino)-ethylamino]-bicyclo[3.2.1]oct-3-yl}-1,3-dipropyl-3,7-dihydro-purine-2,6-dione. MS (M+1 525)

Example 52e: 1,3-Dipropyl-8-{8-(2-pyridin-2-yl-ethylamino)-bicyclo[3.2.1]oct-3-yl}-3,7-dihydro-purine-2,6-dione. MS (M+1 465).

15 Example 52f: Trifluoro-acetic acid; 8-{8-[2-(2-methyl-5-nitro-imidazol-1-yl)-ethylamino]-bicyclo[3.2.1]oct-3-yl}-1,3-dipropyl-3,7-dihydro-purine-2,6-dione. MS (M+1 513).

Example 52g: (1H-Benzoimidazol-2-ylmethyl)-[3-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-yl]-ammonium; trifluoro-acetate.. MS (M+1 490).

Example 53

(1H-Benzoimidazol-2-ylmethyl)-[3-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-ylmethyl]-ammonium; trifluoro-acetate

25 Followed the same reductive amination procedure as described in Example 52. The title compound was synthesized by using 3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]octane-8-carbaldehyde and C-(1H-Benzoimidazol-2-yl)-methylamine as starting material. MS (M+1 514).

The following compounds were made in an analogous fashion:

30 Example 53a: [3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-ylmethyl]-(3-imidazol-1-yl-propyl)-ammonium; trifluoro-acetate. MS (M+1 482).

Example 53b: (2-tert-Butoxycarbonylamino-ethyl)-[3-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-ylmethyl]-ammonium; trifluoro-acetate. MS (M+1 517).

Example 53bc [3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-ylmethyl]-thiophen-2-ylmethyl-ammonium; trifluoro-acetate. MS (M+1 470).

Example 53d: [2-(5-Dimethylamino-naphthalene-1-sulfonylamino)-ethyl]-[3-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-ylmethyl]-ammonium; trifluoro-acetate. MS (M+1 650).

Example 53e: [3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-ylmethyl]-[2-(1H-indol-3-yl)-ethyl]-ammonium; trifluoro-acetate. MS (M+1 517).

Example 53f: [3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-ylmethyl]-[2-(5-nitro-pyridin-2-ylamino)-ethyl]-ammonium; trifluoro-acetate. MS (M+1 539).

Example 53g: [3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-ylmethyl]-(2-pyridin-2-yl-ethyl)-ammonium; trifluoro-acetate MS (M+1 479).

Example 53h: [2-(1H-Benzoimidazol-2-yl)-ethyl]-[3-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-ylmethyl]-ammonium; trifluoro-acetate MS (M+1 518).

Example 53i: [2-(1H-Benzoimidazol-2-yl)-ethyl]-[3-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]oct-8-yl]-ammonium; trifluoro-acetate MS (M+1 504).

Example 54

8-(3-Oxo-4-aza-tricyclo[3.2.1.0^{2,7}]oct-6-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

8-(5-Oxo-tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (150 mg) was taken in HOAc (5 ml) and H₂NOSO₃H (100 mg) was added and refluxed for 5 hrs. Cooled to room temperature, treated with ice, sat NaHCO₃, extracted with ethyl acetate, washed with brine, and dried over MgSO₄. After concentration, the crude product was crystallized from acetone/water. Yield (135 mg). Mass (ES⁺ 358).

Example 55**1,3-Dipropyl-7-pyrrolidin-1-ylmethyl-3,7-dihydro-purine-2,6-dione**

A solution of 1,3-dipropyl-3,9-dihydro-purine-2,6-dione (446 mg, 1.89 mmol), 37% aqueous formaldehyde (1.2 eq, 2.26 mmol, 0.190 ml) and pyrrolidine (1.2 eq, 2.26 mmol, 161 mg) in EtOH (25 ml) was heated at reflux for 36 h. The cool reaction mixture was concentrated *in vacuo* to give a solid that was dried *in vacuo* for 24 h (598 mg, 99%). ¹H NMR (300 MHz, CDCl₃); δ 0.94 (coincident t, 6H), 1.64 (m, 2H), 1.75 (m, 4H), 1.78 (m, 2H, partially-obscured), 2.69 (m, 2H), 4.00 (m, 4H), 5.30 (s, 2H), 7.59 (s, 1H); MS: 320 (MH⁺).

Example 56**8-(3-Hydroxy-8-oxa-bicyclo[3.2.1]oct-6-en-3-yl)-1,3-dipropyl-3,9-dihydro-purine-2,6-dione**

To a stirred solution of 1,3-dipropyl-7-pyrrolidin-1-ylmethyl-3,7-dihydro-purine-2,6-dione (Example 48) (522 mg, 1.63 mmol) in THF (50 ml) at -78 °C was added n-BuLi (1.55 M in hexanes, 1.2 eq, 1.3 ml). The color of the resulting yellow mixture deepened to orange-red and was stirred at this temperature for 0.5 h. A solution of 8-oxa-bicyclo[3.2.1]oct-6-en-3-one (1.1 eq, 222 mg, 1.79 mmol) in THF (4 ml) was added via syringe over a period of 20 minutes. The mixture was held at -78 °C for 2 h and allowed to reach ambient temperature overnight (12 h). The reaction mixture was partitioned between saturated aqueous NH₄Cl (20 ml) and EtOAc (20 ml) and the aqueous phase was extracted with EtOAc (20 ml). The combined organic extracts were washed with saturated aqueous NaCl (20 ml), dried (MgSO₄), filtered and concentrated *in vacuo*. The resulting orange oil was purified by chromatography on silica using 5% MeOH in CH₂Cl₂ as eluent to give a clear oil that solidified upon standing (50 mg, 8 %).

¹H NMR (300 MHz, CDCl₃); δ 0.94 (coincident t, 6H), 1.66 (m, 2H), 1.77 (m, 2H), 1.83 (d, 2H, J = 14.6 Hz), 2.77 (dd, 2H, J = 4.0, 14.7 Hz), 3.97 (t, 2H), 4.05 (t, 2H), 4.30 (br s, 1H), 4.91 (d, 2H, J = 3.7 Hz), 6.59 (s, 2H); MS: 361 (MH⁺).

Example 57**8-(8-Oxa-bicyclo[3.2.1]oct-6-en-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione**

To an ice-cold suspension of (methoxymethyl)triphenylphosphonium chloride (1.77 mmol, 0.61 g) in PhMe (6 ml) was added a solution of potassium hexamethyldisilazide (0.5 M, 3.48 ml). The resulting red-orange mixture was stirred at ice temperature for 30 min. To the cold mixture was added 8-oxa-bicyclo[3.2.1]oct-6-en-3-one (Mann, J. et al., *J. Chem. Soc. Perkin Trans I* 1992, 787) (1.61 mmol, 0.200 g) as a solution in PhMe (6 ml). The reaction was stirred overnight with warming to room temperature and then partitioned between saturated NH_4Cl and Et_2O . The aqueous was extracted with Et_2O and the combined organic extracts washed with saturated NH_4Cl , H_2O , and brine and dried (MgSO_4). Filtration and evaporation followed by flash column chromatography, eluting with an $\text{Et}_2\text{O}/\text{CH}_2\text{Cl}_2$ gradient provided the desired product (0.179 g, 73%) as a yellow liquid. TLC (silica, 1:1 Et_2O /hexanes, I_2 visualization) R_f (desired product) = 0.59

To a solution of 3-methoxymethylene-8-oxa-bicyclo[3.2.1]oct-6-ene (1.18 mmol, 0.18 g) in THF (1.2 ml) was added at room temperature 1N HCl (1.2 ml). The reaction was stirred overnight at room temperature, then quenched with 5% NaHCO_3 and extracted with Et_2O . The combined organic extracts were washed with 5% NaHCO_3 , brine and dried (MgSO_4). Filtration and evaporation provided the title compound (0.155 g, 95%) as an oil. TLC(silica, 1:1 Et_2O /hexanes, I_2 visualization) R_f (desired product) = 0.22

To a solution of 8-oxa-bicyclo[3.2.1]oct-6-ene-3-carbaldehyde (0.434 mmol, 0.060 g) in EtOH (2.2 ml) at room temperature was added 1N NaOH (2.2 ml) followed by Ag_2O (0.521 mmol, 0.121 g). The reaction, which became slightly warm, was stirred briskly 1h. The mixture was filtered on a pad of Celite, rinsing the flask and cake with 1:1 EtOH/ H_2O . The filtrate was concentrated to remove the bulk of the EtOH and the aqueous residue extracted with Et_2O . These extracts were discarded. The aqueous phase was acidified (pH 4) with conc. HCl and extracted with Et_2O . These extracts were washed with brine and dried (MgSO_4). Filtration and evaporation provided the desired product (0.0386 g, 58%) as an oil that solidified on standing. By ^1H NMR analysis, the endo isomer was not detected. ^1H NMR (300 MHz, CDCl_3): 1.67 (br dd, 2H, $J = 5.88, 13.7$ Hz), 1.92 (ddd, 2H, $J = 3.62, 11.6, 13.7$ Hz), 2.80 (tt, 1H, $J = 5.88, 11.6$ Hz), 4.78 (br s, 2H), 6.16 (s, 2H).

To a solution of 8-oxa-bicyclo[3.2.1]oct-6-ene-3-carboxylic acid (0.25 mmol, 0.0386 g), HATU (0.25 mmol, 0.0952 g), and 5,6-diamino-1,3-dipropyl-1H-pyrimidine-2,4-

dione hydrochloride (Daly, J.W. et al., *J. Med. Chem.*, 1985, 28 (4), 487) (0.25 mmol, 0.0658 g) in DMF (2.5 ml) was added iPr₂NEt (0.75 mmol, 0.13 ml). The reaction was stirred overnight at room temperature. It was concentrated at the pump to remove DMF. The residue was dissolved in EtOAc and washed with 1N HCl, 5% NaHCO₃, and brine and dried (MgSO₄). Filtration and evaporation followed by flash column chromatography, eluting with a THF/CH₂Cl₂ gradient provided the desired product (0.067 g, 74%) as an oil that solidified on standing. ¹H NMR (300 MHz, CDCl₃): 0.90 (t, 3H, J = 7.4 Hz), 0.97 (t, 3H, J = 7.3 Hz), 1.53-1.72 (m, 6H), 1.95-2.03 (m, 2H), 3.0 (br m, 1H), 3.82-3.91 (m, 4H), 4.79 (br s, 2H), 6.18 (s, 2H).

A solution of 8-oxa-bicyclo[3.2.1]oct-6-ene-3-carboxylic acid (6-amino-2,4-dioxo-1,3-dipropyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-amide (0.185 mmol, 0.067 g) in 20% NaOH (1.23 ml) and MeOH (6.2 ml) was stirred and refluxed overnight. The reaction was cooled to room temperature and then concentrated to remove MeOH. The aqueous residue was extracted with Et₂O and these extracts discarded. The aqueous was acidified (pH 2-3) with conc. HCl and then extracted with EtOAc. The combined EtOAc extracts were washed with H₂O and brine and dried (MgSO₄). Filtration and evaporation followed by flash column chromatography, eluting with 1:1 EtOAc/CH₂Cl₂, provided the title compound (0.037 g, 58%) as a beige solid. ¹H NMR (300 MHz, CDCl₃): 0.93-0.99 (m, 6H), 1.62-1.83 (m, 6H), 2.14-2.25 (m, 2H), 3.40-3.51 (m, 1H), 4.05-4.10 (m, 4H), 4.86 (br s, 2H), 6.25 (s, 2H).

Example 58

8-(8-Oxa-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione

To a solution of 8-(8-Oxa-bicyclo[3.2.1]oct-6-en-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione (Example 50) (0.029 mmol, 0.010 g) in MeOH (5 ml) was added 10% Pd/C (50% H₂O) and the resulting suspension stirred briskly under H₂ (1 atm) for 2h. The mixture was filtered through Celite and the cake rinsed with MeOH. Filtration and evaporation followed by purification by PLC, eluting with 1:1 EtOAc/CH₂Cl₂, provided the title compound (0.010 g, 100%). ¹H NMR (300 MHz, CDCl₃): 0.93-0.99 (m, 6H), 1.68-1.89 (m, 8H), 2.04-2.07 (m, 2H), 2.16-2.25 (m, 2H), 3.34-3.42 (m, 1H), 4.05-4.12 (m, 4H), 4.50 (br s, 2H), 8.9 (br s, 1H).

Example 59**1,3-Dipropyl-7-(tetrahydro-pyran-2-yl)-3,7-dihydro-purine-2,6-dione.**

A suspension of 1,3-dipropyl-3,9-dihydro-purine-2,6-dione (1.0 g, 4.2 mmol) and PPTS (0.42 mmol, 106 mg) in 3,4-dihydropyran (15 ml) and CHCl_3 (5 ml) was stirred at room temperature for 48 h. The solvent was removed *in vacuo* to give a pale yellow solid that was dissolved in CH_2Cl_2 , washed with water (2 x 20 ml), dried (Na_2SO_4), filtered and concentrated *in vacuo* to give a white solid (1.2 g, 89%). MS: 343 (MH^+).

Example 60**3-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-3-hydroxy-8-oxa-bicyclo[3.2.1]octane-6,7-dicarboxylic acid dimethyl ester**

A solution of LDA was prepared at -78°C by addition of *n*-BuLi (1.8 M in hexanes, 1.7 ml) to a solution of iPr_2NH (3.61 mmol, 0.506 ml) in THF (25 ml). After addition, the LDA was aged at -78°C for 45 min. To this was added slowly at -78°C a solution of 1,3-dipropyl-7-(tetrahydropyran-2-yl)-3,7-dihydropurine-2,6-dione (Example 52) (2.78 mmol, 0.89 g) in THF (35 ml). After stirring another 1 h at -78°C , a solution of 8-oxa-bicyclo[3.2.1]oct-6-en-3-one (Mann, J. et al., *J. Chem. Soc. Perkin Trans I* 1992, 787) (2.78 mmol, 0.345 g) in THF (5 ml) was added. The reaction was stirred overnight with warming to room temperature. It was quenched by addition of saturated NH_4Cl and extracted with EtOAc. The combined organic extracts were washed with saturated NH_4Cl , H_2O and brine, and dried (MgSO_4). Filtration and evaporation followed by flash column chromatography, eluting with an EtOAc/ CH_2Cl_2 gradient, provided the desired product (0.55 g, 45%). MS (ESP+, 60V): 445.07 (M+H, 35%), 361.06 (48%), 343.05 (100%).

A solution of 8-(3-hydroxy-8-oxa-bicyclo[3.2.1]oct-6-en-3-yl)-1,3-dipropyl-7-(tetrahydropyran-2-yl)-3,7-dihydropurine-2,6-dione (0.113 mmol, 0.050 g) and Et_3N (1.13 mmol, 0.16 ml) in MeOH (3 ml) was saturated with CO bubbled in from a lecture bottle over 30 min. To the reaction was then added PdCl_2 (0.023 mmol, 0.0041 g) and CuCl_2 (0.339 mmol, 0.046 g). The reaction was stirred overnight at room temperature under a static atmosphere of CO. The completed reaction was quenched by the addition of concentrated NH_4OH , diluted with EtOAc and filtered through Celite to remove solids. The biphasic filtrate was separated and the aqueous extracted with EtOAc. The combined organics were washed with 1N HCl, saturated NaHCO_3 , H_2O and brine, and dried (MgSO_4). Filtration and

evaporation provided the desired product (0.060 g, 94%). MS (ESP+, 60V): 563.13 (M+H, 28%), 479.10 (100%).

To a solution of 3-[2,6-dioxo-1,3-dipropyl-7-(tetrahydropyran-2-yl)-2,3,6,7-tetrahydro-1*H*-purin-8-yl]-3-hydroxy-8-oxa-bicyclo[3.2.1]octane-6,7-dicarboxylic acid dimethyl ester (0.060 mmol, 0.030 g) in 1:1 THF/ MeOH (6 ml) was added 1N HCl (3 drops). The reaction was stirred at room temperature 3d and then concentrated to dryness. The residue was purified by PLC on a 1mm layer, eluting with 20% THF/CH₂Cl₂, providing the title compound (0.0162 g, 56%). ¹³C NMR (100 MHz, CDCl₃): 11.53 (q), 11.50 (q), 21.72 (t), 21.75 (t), 41.74 (t), 43.82 (t), 45.85 (t), 51.02 (d), 52.64 (q), 70.37 (s), 77.12 (d), 107.53 (s), 149.12 (s), 151.17 (s), 156.32 (s), 159.98 (s), 173.36 (s).

Example 61

8-(3-Hydroxy-6,7-bis-hydroxymethyl-8-oxa-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-3,7-dihydropurine-2,6-dione

To a solution of 3-[2,6-dioxo-1,3-dipropyl-7-(tetrahydropyran-2-yl)-2,3,6,7-tetrahydro-1*H*-purin-8-yl]-3-hydroxy-8-oxa-bicyclo[3.2.1]octane-6,7-dicarboxylic acid dimethyl ester (Example 53) (0.060 mmol, 0.030 g) in THF (3ml) was added a solution of LiBH₄ (2M, 0.050 ml). The reaction was stirred at room temperature 3d. It was then carefully quenched by addition of 1N HCl and extracted with EtOAc. The combined organic extracts were washed with saturated NaHCO₃ (1X) and brine, and dried (MgSO₄). Filtration and evaporation provided the desired product (0.028 g, 92%) as an oil. MS (ESP+, 60V): 529.7 (M+Na, 20%), 507.32 (M+H, 43%), 423.20 (87%), 223.08 (100%).

To a solution of 8-(3-hydroxy-6,7-bis-hydroxymethyl-8-oxa-bicyclo[3.2.1]oct-3-yl)-1,3-dipropyl-7-(tetrahydropyran-2-yl)-3,7-dihydropurine-2,6-dione (0.059 mmol, 0.030 g) in 1:1 THF/ MeOH (6 ml) was added 1N HCl (0.5 ml). The reaction was stirred at room temperature overnight and then concentrated to dryness. The residue was purified by reverse phase HPLC, providing the title compound (0.0024 g, 10%). MS (ESP+, 60V): 423.15 (M+H, 100%); MS (ESP-, 60V): 421.01 (M-H, 100%)

Example 62**4-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo-[3.2.1]octane-1-carboxylic acid**

Using the procedure described in Example 50, 4-oxo-bicyclo[3.2.1]octane-1-carboxylic acid ethyl ester (Kraus, W., et al. *Liebigs Ann.Chem.* **1981**, *10*, 1826; Kraus, W., et al. *Tetrahedron Lett.* **1978**, 445; Filippini, M.-H. et al. *J. Org. Chem.* **1995**, *60*, 6872) (6.17 mmol, 1.21 g) was converted to the desired product. Flash chromatography, eluting with 10% Et₂O/hexanes provided pure product (0.96 g, 69%) as a liquid (mixture of E/Z isomers). ¹³C NMR (100 MHz, CDCl₃): 14.31 (q), 19.15 (t), 22.97 (t), 23.61 (t), 23.91 (t), 29.97 (t), 31.13 (t), 32.04 (t), 32.36 (t), 34.61 (t), 34.85 (d), 35.81 (t), 43.18 (t), 43.63 (t), 50.47 (s), 50.77 (s), 59.63 (q), 59.69 (t), 121.04 (s), 121.44 (s), 137.18 (d), 138.16 (d), 177.60 (s), 177.63 (s).

Using the procedure described in Example 50, 4-methoxymethylene-bicyclo[3.2.1]octane-1-carboxylic acid ethyl ester (3.84 mmol, 0.86 g) was converted to the desired product (0.81 g, 100%). TLC(silica, 20% Et₂O/ hexanes, 20% PMA/EtOH visualization) R_f (desired product) = 0.29.

To an ice-cold solution of 4-formyl-bicyclo[3.2.1]octane-1-carboxylic acid ethyl ester (3.85 mmol, 0.81 g) was added slowly Jones reagent (2.7 M, 1.43 ml). The reaction was stirred at ice temperature 20 min, then quenched by addition of iPrOH, diluted with H₂O and extracted with Et₂O. The combined organic extracts were washed with H₂O, brine, and dried (MgSO₄). Filtration and evaporation provided the viscous oily desired product (0.76 g, 87%) as a mixture of axial and equatorial acids. ¹³C NMR (100 MHz, CDCl₃): 14.16 (q), 19.86 (t), 21.07 (t), 25.98 (t), 29.20 (t), 31.52 (t), 31.87 (t), 32.27 (t), 33.39 (t), 37.80 (d), 38.07 (t), 38.10 (d), 42.06 (t), 44.80 (d), 45.78 (d), 49.38 (s), 49.60 (s), 60.31 (t), 60.36 (t), 177.08 (s), 180.01 (s).

Using the procedure described in Example 50, Step D, bicyclo[3.2.1]octane-1,4-dicarboxylic acid 1-ethyl ester (0.84 mmol, 0.19 g) was reacted with 5,6-diamino-1,3-dipropyl-1H-pyrimidine-2,4-dione hydrochloride (0.84 mmol, 0.22 g) to provide the desired product (0.36 g, 100%) as a mixture of axial and equatorial amides. MS (ESP+, 60V): 456.95 (M+Na, 45%), 435.00 (M+H, 8%), 325.12 (42%), 280.05 (100%).

Using the procedure described in Example 50, 4-(6-amino-2,4-dioxo-1,3-dipropyl-1,2,3,4-tetrahydro-pyrimidin-5-ylcarbamoyl)-bicyclo[3.2.1]octane-1-carboxylic acid ethyl

ester (0.84 mmol, 0.36 g) was converted to the title compound. Flash chromatography eluting with 95:5:0.1 CH₂Cl₂/THF/AcOH provided partial separation of the axial (first band, 0.032 g) and equatorial (second band, 0.055 g) isomers. MS (ESP+, 60V): (axial isomer) 389.12 (M+H, 100%), 343.11 (15%); (equatorial isomer) 389.12 (M+H, 100%), 347.05 (8%)

5

Example 63

4-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo-[3.2.1]oct-3-ene-1-carboxylic acid

To a solution of 4-oxo-bicyclo[3.2.1]octane-1-carboxylic acid ethyl ester (Kraus, W., et al. *Liebigs Ann. Chem.* 1981, 10, 1826; Kraus, W., et al. *Tetrahedron Lett.* 1978, 445; Filippini, M.-H. et al. *J. Org. Chem.* 1995, 60, 6872) (0.51 mmol, 0.100 g) in THF (2.5 ml) at -78°C was added LiHMDS (1.0 M in THF, 0.56 ml). After 1h at -78°C, a solution of PhNTf₂ (0.56 mmol, 0.200 g) in THF (1 ml) was added. The reaction was stirred overnight with warming to room temperature. The completed reaction was concentrated to dryness and the residue purified by passage through a pad of silica gel, eluting with EtOAc/CH₂Cl₂. Evaporation of the filtrate provide the desired product (0.15 g, 90%).

A solution of 4-trifluoromethanesulfonyloxy-bicyclo[3.2.1]oct-3-ene-1-carboxylic acid ethyl ester (0.46 mmol, 0.15 g), 5,6-diamino-1,3-dipropyl-1H-pyrimidine-2,4-dione hydrochloride (0.55 mmol, 0.146 g), iPr₂NEt (0.92 mmol, 0.16 ml), Pd(OAc)₂ (0.02 mmol, 0.0046 g) and Ph₃P (0.035 mmol, 0.0092 g) in DMF (5 ml) was saturated with CO bubbled in from a lecture bottle over 30 min. The reaction was then stirred and heated 6h at 100°C under a static atmosphere of CO. The DMF was removed at the pump. The residue was dissolved in EtOAc, washed with 1N HCl, saturated NaHCO₃, H₂O, and brine and dried (MgSO₄). Filtration and evaporation followed by flash chromatography, eluting with 10% THF/CH₂Cl₂ provided pure desired product (0.054 g, 27%) as an oil. MS (ESP+, 60V): 455.16 (M+Na, 13%), 433.1 (M+H, 15%), 439.15 (27%), 182.93 (100%).

Using the procedure described in Example 50, 4-(6-amino-2,4-dioxo-1,3-dipropyl-1,2,3,4-tetrahydro-pyrimidin-5-ylcarbonyl)-bicyclo[3.2.1]oct-3-ene-1-carboxylic acid ethyl ester (0.125 mmol, 0.054 g) was converted to the title compound. Pure material (0.0031 g, 6.5%) was obtained by reverse phase HPLC. MS (ESP+, 60V): 387.06 (M+H, 100%).

Example 64

1,3-Dipropyl-7-(tetrahydro-pyran-2-yl)-3,7-dihydro-purine-2,6-dione

A suspension of 1,3-dipropyl-3,9-dihydro-purine-2,6-dione (1.0 g, 4.2 mmol) and PPTS (0.42 mmol, 106 mg) in 3,4-dihydropyran (15 ml) and CHCl_3 (5 ml) was stirred at room temperature for 48 h. The solvent was removed *in vacuo* to give a pale yellow solid that was dissolved in CH_2Cl_2 , washed with water (2 x 20 ml), dried (Na_2SO_4), filtered and concentrated *in vacuo* to give a white solid (1.2 g, 89%). MS: 343 (MH^+).

Example 65

106 xanthine derivatives were prepared, having the structures indicated in FIG. 1. For some of these compounds, the K_i values for rat and human adenosine A_1 receptors and for human adenosine A_{2a} receptors were determined according to the following binding assay protocol. The ratio A_{2a}/A_1 was also calculated.

Materials

Adenosine deaminase and HEPES were purchased from Sigma (St. Louis, MO). Ham's F-12 cell culture medium and fetal bovine serum were purchased from GIBCO Life Technologies (Gaithersburg, MD). Antibiotic G-418, Falcon 150-mM culture plates and Costar 12-well culture plates were purchased from Fisher (Pittsburgh, PA). [^3H]CPX was purchased from DuPont-New England Nuclear Research Products (Boston, MA). Penicillin/streptomycin antibiotic mixture was purchased from Mediatech (Washington, DC). The composition of HEPES-buffered Hank's solution was: 130 mM NaCl, 5.0 mM Cl, 1.5 mM CaCl_2 , 0.41 mM MgSO_4 , 0.49 mM Na_2HPO_4 , 0.44 mM KH_2PO_4 , 5.6 mM dextrose, and 5 mM HEPES (pH 7.4).

Membrane preparation

Rat A_1 Receptor: Membranes were prepared from rat cerebral cortex isolated from freshly euthanized rats. Tissues were homogenized in buffer A (10 mM EDTA, 10 mM Na-HEPES, pH 7.4) supplemented with protease inhibitors (10 $\mu\text{g}/\text{ml}$ benzamidine, 100 μM PMSF, and 2 $\mu\text{g}/\text{ml}$ each of aprotinin, pepstatin and leupeptin), and centrifuged at 20,000 x g for 20 min. Pellets were resuspended and washed twice with buffer HE (10 mM Na-HEPES, 1 mM EDTA, pH 7.4, plus protease inhibitors). Final pellets were resuspended in buffer HE, supplemented with 10% (w/v) sucrose and protease inhibitors, and frozen in aliquots at -80°C . Protein concentrations were measured using BCA protein assay kit (Pierce).

Human A₁ Receptor: Human A₁ adenosine receptor cDNA was obtained by RT-PCR and subcloned into pcDNA3.1(Invitrogen). Stable transfection of CHO-K1 cells was performed using LIPOFECTAMINE-PLUS (GIBCO-BRL) and colonies were selected in 1 mg/ml G418, and screened using radioligand binding assays. For membrane preparations, CHO-K1 cells growing as monolayers in complete media (F12+10%FCS+1mg/ml G418) were washed in PBS and harvested in buffer A supplemented with protease inhibitors. Cells were homogenized, centrifuged, and washed twice with buffer HE as described above. Final pellets were stored in aliquots at -80°C.

Radioligand binding assays

Membranes (50µg membrane protein for rat A₁ARs, and 25µg of CHO-K1 membrane protein for human A₁ARs), radioligands and varying concentrations of competing ligands were incubated in triplicates in 0.1 ml buffer HE plus 2 units/ml adenosine deaminase for 2.5 h at 21°C. Radioligand [³H]DPCPX (112 Ci/mmol from NEN, final concentration: 1nM) was used for competition binding assays on A₁ARs. Nonspecific binding was measured in the presence of 10 µM BG9719. Binding assays were terminated by filtration over Whatman GF/C glass fiber filters using a BRANDEL cell harvester. Filters were rinsed three times with 3-4 ml ice-cold 10 mM Tris-HCl, pH 7.4 and 5 mM MgCl₂ at 4°C. Filter paper was transferred to a vial, and 3ml of scintillation cocktail ScintiVerseII (Fisher) was added. Radioactivity was counted in a Wallac β-counter.

Analysis of binding data

For K_i Determinations: Competition binding data were fit to a single-site binding model and plotted using Prism GraphPad. Cheng-Prusoff equation $K_i = IC_{50}/(1+[I]/K_D)$ was used to calculate K_i values from IC₅₀ values, where K_i is the affinity constant for the competing ligand, [I] is the concentration of the free radioligand, and K_D is the affinity constant for the radioligand.

For % Binding: For one-point binding assays, data were presented as % of total specific binding at 1 µM of competing compound: % of total = 100* (Specific binding with 1 µM of competing compound/ total specific binding).

Results

All of the compounds tested exhibited rat A₁ K_i values between 0.47 and 1225 nM, human A₁ K_i values between 12 and 1000 nM, and human A_{2a} K_i values between 18 and

100,000 nM. All of the compounds but one had A_{2a}/A_1 ratios of at least 8, most greater than 50, a substantial number greater than 100, and at least one greater than 200.

Example 66

Alternative Assay Methodology

Materials

See Example 65.

Cell Culture

CHO cells stably expressing the recombinant human A_1 AdoR (CHO: A_1 AdoR cells) were prepared as described (Kollias-Barker et al., *J. Pharma. Exp. Ther.* **281**(2), 761, 1997) and cultured as for CHO:Wild cells. CHO cells were cultured as monolayers on plastic dishes in Ham's F-12 medium supplemented with 10% fetal bovine serum, 100 U penicillin G and 100 μ g streptomycin in a humidified atmosphere of 5% CO₂/95% air at 37°C. The density of [³H]CPX binding sites in CHO cells was 26 ± 2 (n=4) fmol/mg protein. Cells were subcultured twice weekly after detachment using 1 mM EDTA in Ca²⁺-Mg²⁺-free HEPES-buffered Hank's solution. Three different clones of CHO: A_1 AdoR cells were used for experiments, and all results were confirmed with cells from two or three clones. The density of A_1 AdoRs in these cells was 4000-8000 fmol/mg protein, as determined by assay of [³H]CPX specific binding.

Radioligand Binding

CHO cells grown on 150 mm culture dishes were rinsed with HEPES-buffered Hank's solution, then removed with a cell scraper and homogenized in ice-cold 50 mM Tris-HCl, pH 7.4. Cell membranes were pelleted by centrifugation of the cell homogenate at 48,000 x g for 15 minutes. The membrane pellet was washed twice by resuspension in fresh buffer and centrifugation. The final pellet was resuspended in a small volume of 50 mM Tris-HCl, pH 7.4, and stored in aliquots of 1 ml at -80°C until used for assays.

To determine the density of A_1 AdoRs in CHO cell membranes, 100 μ l aliquots of membranes (5 μ g protein) were incubated for 2 hours at 25°C with 0.15-20 nM [³H]CPX and adenosine deaminase (2 U/ml) in 100 μ l of 50 mM Tris-HCl, pH 7.4. Incubations were terminated by dilution with 4 ml of ice-cold 50 mM Tris-HCl buffer and immediate collection of membranes onto glass-fiber filters (Schleicher and Schuell, Keene, NH) by vacuum filtration (Brandel, Gaithersburg, MD). Filters were washed quickly three times

with ice-cold buffer to remove unbound radioligand. Filter discs containing trapped membranes bound radioligand were placed in 4 ml of Scintiverse BD (Fisher), and the radioactivity was quantified using a liquid scintillation counter. To determine nonspecific binding of [3 H]CPX, membranes were incubated as described above and 10 μ M CPT was added to the incubation buffer. Nonspecific binding was defined as [3 H]CPX bound in the presence of 10 μ M CPT. Specific binding of the radioligand to the A₁AdoR was determined by subtracting nonspecific binding from total binding. Nonspecific binding was found to increase linearly with an increase of [3 H]CPX concentration. Triplicate assays were done at each tested concentration of [3 H]CPX.

To determine the affinities of antagonists of A₁AdoRs for the human recombinant A₁AdoR expressed in CHO cells, binding of 2 nM [3 H]CPX in the presence of increasing concentrations of antagonist was measured. Aliquots of CHO cell membranes (100 μ l: 5 μ g protein), [3 H]CPX, antagonist (0.1 nM – 100 μ M), and adenosine deaminase (2 U/ml) were incubated for 3 hours at 25°C in 200 μ l of 50 mM Tris-HCl buffer (pH 7.4). Assays were terminated as described above.

Data Analysis


Binding parameters (i.e., B_{max}, K_d, IC₅₀, K_i, and Hill coefficients) were determined using the radioligand binding analysis program LIGAND 4.0 (Elsevier-Biosoft). Most of the compounds tested exhibited A_{2a}/A₁ ratios of at least 20, a substantial number were greater than 50, and some were greater than 100.

Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

What is claimed is:

1. A compound comprising the formula:




wherein R_1 and R_2 , independently, are selected from the group consisting of:

- a) hydrogen;
- b) alkyl, alkenyl of not less than 3 carbons, and alkynyl of not less than 3 carbons; wherein the alkyl, alkenyl, or alkynyl is either unsubstituted or functionalized with one or two substituents selected from the group consisting of hydroxy, alkoxy, amino, alkylamino, dialkylamino, heterocyclyl, acylamino, alkylsulfonylamino, and heterocyclylcarbonylamino; and

- c) aryl and substituted aryl;

R_3 is a bicyclic or tricyclic group selected from the group consisting of:




wherein the bicyclic or tricyclic group is either unsubstituted or functionalized with one or more substituents selected from the group consisting of :

- (a) alkyl, alkenyl, and alkynyl; wherein the alkyl, alkenyl, and alkynyl are either unsubstituted or functionalized with one or more substituents selected from the group consisting of alkoxy, alkoxycarbonyl, alkoxycarbonylaminoalkylamino, aralkoxycarbonyl, -R₅, dialkylamino, heterocyclalkylamino, hydroxy, substituted arylsulfonylaminoalkylamino, and substituted heterocyclaminoalkylamino;
- (b) acylaminoalkylamino, alkenylamino, alkoxycarbonyl, alkoxycarbonyl, alkoxycarbonylalkylamino, alkoxycarbonylaminoacyloxy, alkoxycarbonylaminoalkylamino, alkylamino, amino, aminoacyloxy, carbonyl, -R₅, R₅-alkoxy, R₅-alkylamino, dialkylaminoalkylamino, heterocycl, heterocyclalkylamino, hydroxy, phosphate, substituted arylsulfonylaminoalkylamino, substituted heterocycl, and substituted heterocyclaminoalkylamino;

R₄ is selected from the group consisting of -H, -C₁₋₄-alkyl, -C₁₋₄-alkyl-CO₂H, and phenyl; and is either unsubstituted or functionalized with one or more substituents selected from the group consisting of halogen, -OH, -OMe, -NH₂, NO₂ or benzyl, optionally substituted with one to three groups selected from halogen, -OH, -OMe, -NH₂, and -NO₂;

R₅ is selected from the group consisting of -CH₂COOH, -C(CF₃)₂OH, -CONHNHSO₂CF₃, -CONHOR₄, -CONHSO₂R₄, -CONHSO₂NHR₄, -C(OH)R₄PO₃H₂, -NHCOCF₃, -NHCONHSO₂R₄, -NHPO₃H₂, -NHSO₂R₄, -NHSO₂NHCOR₄, -OPO₃H₂, -OSO₃H, -PO(OH)R₄, -PO₃H₂, -SO₃H, -SO₂NHR₄, -SO₃NHCOR₄, -SO₃NHCONHCO₂R₄, and:



X_1 and X_2 are independently selected from O and S;

Z is selected from the group consisting of a single bond, $-O-$, $-(CH_2)_{1-3}-$, $-O(CH_2)_{1-2}-$,

$-CH_2OCH_2-$, $-(CH_2)_{1-2}O-$, $-CH=CHCH_2-$, $-CH=CH-$, and $-CH_2CH=CH-$; and

R_6 is selected from the group consisting of hydrogen, alkyl, acyl, alkylsulfonyl, aralkyl, substituted aralkyl, substituted alkyl, and heterocyclyl. The compound of claim 1, wherein the compound is in a form selected from the group consisting of an achiral compound, a racemate, an optically active compound, a pure diastereomer, a mixture of diastereomers, and a pharmacologically acceptable addition salt.

2. The compound of claim 1, wherein R_1 and R_2 are each alkyl groups.

3. The compound of claim 1, wherein R_1 and R_2 are each n-propyl.

4. The compound of claim 3, wherein Z is a single bond.

5. The compound of claim 1, wherein R_3 is selected from the group consisting of:



and is functionalized with one or more substituents selected from carbonyl, hydroxy, alkenyl, alkenyloxy, hydroxyalkyl, carboxy, carboxyalkenyl, carboxyalkyl, aminoacyloxy, carboxyalkoxy, dialkylaminoalkenyl, and dialkylaminoalkyl.

6. The compound of claim 1, wherein R_3 is:



and is functionalized with one or more substituents selected from carbonyl, hydroxy, alkenyl, carboxyalkenyl, hydroxyalkyl, dialkylaminoalkenyl, and dialkylaminoalkyl.

7. The compound of claim 6, wherein R_3 is substituted with a substituent selected from the group consisting of hydroxy, hydroxyalkyl, dialkylaminoalkenyl, and dialkylaminoalkyl.


1 8. The compound of claim 1, wherein the compound is 8-(5-Hydroxy-
2 tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

1 9. The compound of claim 1, wherein the compound is 8-(5-Hydroxymethyl-
2 tricyclo[2.2.1.0^{2,6}]hept-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

3 10. The compound of claim 1, wherein the compound is 8-[5-(3-
4 Dimethylaminopropylidene)-tricyclo[2.2.1.0^{2,6}]hept-3-yl]-1,3-dipropyl-3,7-dihydro-
5 purine-2,6-dione.

1 11. The compound of claim 1, wherein the compound is 8-[5-(3-Dimethylaminopropyl)-
2 tricyclo[2.2.1.0^{2,6}]hept-3-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

1 12. The compound of claim 1, wherein R₃ is selected from



2
3 and is functionalized with one or more substituents selected from the group consisting of
4 hydroxy, carbonyl, alkyl, -R₅, R₅-alkyl, dialkylaminoalkylamino,
5 alkoxy carbonylalkylamino, R₅-alkylamino, heterocyclyl, alkenylamino, amino,
6 alkylamino, heterocyclylalkylamino, acylaminoalkylamino, phosphate,
7 heterocyclylaminoalkylamino, and heterocyclylaminoalkylaminoalkyl.


1 13. The compound of claim 1, wherein R₃ is



2
3 and is functionalized with one or more substituents selected from the group consisting of
4 hydroxy, -R₅, R₅-alkyl, and hydroxyalkyl.

1 14. The compound of claim 1, wherein the compound is 4-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-
2 tetrahydro-1H-purin-8-yl)-bicyclo[3.2.1]octane-1-carboxylic acid.

1 15. The compound of claim 1, wherein R₃ is:




2
3 and is functionalized with one or more substituents selected from the group consisting of
4 alkyl, hydroxy, carbonyl, -R₅, and R₅- alkyl.

1 16. The compound of claim 1, wherein the compound is 8-(4-Hydroxy-bicyclo[3.2.1]oct-6-
2 yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

1 17. The compound of claim 1, wherein the compound is 8-(4-Oxo-bicyclo[3.2.1]oct-6-yl)-
2 1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

1 18. The compound of claim 1, wherein R₃ is:




2
3 and is functionalized with one or more substituents selected from the group consisting of
4 carbonyl, hydroxy, dialkylaminoalkylamino, -R₅, and substituted
5 heterocyclaminoalkylaminoalkyl.

1 19. The compound of claim 1, wherein the compound is 8-[8-(2-Dimethylaminoethylamino)-
2 bicyclo[3.2.1]oct-3-yl]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

1 20. The compound of claim 1, wherein the compound is 8-(8-Hydroxy-bicyclo[3.2.1]oct-3-
2 yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.


1 21. The compound of claim 1, wherein R₃ is:



and is functionalized with one or more substituents selected from the group consisting of carbonyl, hydroxy, and -R5.

22. The compound of claim 1, wherein the compound is 8-(3-Hydroxy-bicyclo[3.2.1]oct-8-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.


23. The compound of claim 5, wherein R₃ is selected from the group consisting of:



and is functionalized with one or more substituents selected from the group consisting of hydroxyalkyl, hydroxy, and alkoxycarbonyl.

24. The compound of claim 1, wherein the compound is 8-(8-Oxa-bicyclo[3.2.1]oct-6-en-3-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

25. The compound of claim 1, wherein R₃ is:



and is functionalized with one or more substituents selected from the group consisting of carbonyl, aralkyloxycarbonylalkyl, and alkoxycarbonylalkyl.

26. The compound of claim 1, wherein the compound is 8-(2-Oxo-3-aza-bicyclo[3.2.1]oct-8-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione.

27. A medicament composition comprising a compound of claim 1 together with a suitable excipient.

28. A method of treating a subject suffering from a condition characterized by an elevated adenosine concentration and/or increased sensitivity to adenosine; the method comprising administering to the subject an effective adenosine antagonizing amount of a compound of claim 1.

1 29. The method of claim 28, wherein the condition is selected from the group consisting of
2 cardiac and circulatory disorders, degenerative disorders of the central nervous system,
3 respiratory disorders, diseases for which diuretic treatment is indicated, Parkinson's
4 disease, depression, traumatic brain damage, post-stroke neurological deficit, respiratory
5 depression, neonatal brain trauma, dyslexia, hyperactivity, cystic fibrosis, cirrhotic
6 ascites, neonatal apnea, renal failure, diabetes, asthma, and edematous conditions.

1 30. The method of claim 28, wherein the condition is selected from the group consisting of
2 congestive heart failure and renal dysfunction.

1 31. A method of making 8-substituted xanthines comprising the steps of:
2 a) obtaining a N7,C8-dihydroxanthine;
3 b) protecting the N7 position of the xanthine;
4 c) deprotonating the C8 position with strong base to generate an anion;
5 d) trapping the anion with a carboxyl, carbonyl, aldehyde, or ketone compound; and
6 e) deprotecting the protected N7 position to obtain an 8-substituted xanthine.

FIG. 1




FIG. 1




FIG. 1




FIG. 1




FIG. 1





FIG. 1



THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 May 2001 (17.05.2001)

PCT

(10) International Publication Number
WO 01/34604 A3

(51) International Patent Classification⁷: C07D 473/06.
A61K 31/52, 31/505, A61P 9/00

(US). PETTER, Russell, C. [US/US]; 343 Hudson Road,
Stow, MA 01775 (US).

(21) International Application Number: PCT/US00/31100

(74) Agents: HALEY, James, F. et al.; Fish & Neave, 1251
Avenue of the Americas, New York, NY 10020 (US).

(22) International Filing Date:
13 November 2000 (13.11.2000)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/165,283 12 November 1999 (12.11.1999) US

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 60/165,283 (CON)
Filed on 12 November 1999 (12.11.1999)

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): BIO-
GEN, INC. [US/US]; 14 Cambridge Center, Cambridge,
MA 02142 (US).


Published:
— with international search report

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): DOWLING, James,
E. [US/US]; 30 Aberdeen Drive, Scituate, MA 02066 (US).
ENSINGER, Carol [US/US]; 76 Stonegate Road, Chelms-
ford, MA 01824 (US). KUMARAVEL, Gnanasamban-
dam [US/US]; 10 Perham Circle, Westford, MA 01886

(88) Date of publication of the international search report:
10 January 2002

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME



(I)

(57) Abstract: The invention is based on the discovery that com-
pounds of Formula (I), are unexpectedly highly potent and selective
inhibitors of the adenosine A₁ receptor. Adenosine A₁ antagonists
can be useful in the prevention and/or treatment of numerous dis-
eases, including cardiac and circulatory disorders, degenerative dis-
orders of the central nervous system, respiratory disorders, and many
diseases for which diuretic treatment is suitable. In one embodiment,
the invention features a compound of formula (I), wherein R₃ is se-
lected from particular bicycloheptyl, bicyclooctyl, tricycloheptyl and
tricyclooctyl groups.

WO 01/34604 A3

INTERNATIONAL SEARCH REPORT

national Application No

PCT/US 00/31100

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D473/06 A61K31/52 A61K31/505 A61P9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DE 40 19 892 A (BOEHRINGER INGELHEIM KG) 2 January 1992 (1992-01-02) page 23 -page 24; claims ---	1-30
Y	EP 0 415 456 A (KYOWA HAKKO KOGYO KK) 6 March 1991 (1991-03-06) claims 1-7; table 1 ---	1-30
Y	J SHIMADA ET AL: "8-Polycycloalkyl-1,3-dipropylxanthines as Potent and Selective Antagonists for A1-Adenosine Receptors" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 35, no. 5, 1992, pages 924-930, XP002160035 ISSN: 0022-2623 page 927; table III --- -/--	1-30

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

9 April 2001

Date of mailing of the international search report

13.07.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Härtinger, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/31100

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>SUZUKI F ET AL: "ADENOSINE A1 ANTAGONISTS. 2. STRUCTURE-ACTIVITY RELATIONSHIPS ON DIURETIC ACTIVITIES AND PROTECTIVE EFFECTS AGAINST ACUTE RENAL FAILURE" JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 35, no. 16, 1992, pages 3066-3075, XP002055503 ISSN: 0022-2623 page 3069; table III -----</p>	1-30

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/31100

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 28-30 are directed to a method of treatment of the human or animal body, the search has been carried out and based on the alleged effects of the compound.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1 - 30

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-30

Xanthine derivatives having the formula depicted in claim 1 with R3 being carbotricycloheptyl; compositions containing the same and methods making use of them.

2. Claims: 1-30

Xanthine derivatives having the formula depicted in claim 1 with R3 being carbobicycloheptyl; compositions containing the same and methods making use of them.

3. Claims: 1-30

Xanthine derivatives having the formula depicted in claim 1 with R3 being carbobicyclooctyl; compositions containing the same and methods making use of them.

4. Claims: 1-30

Xanthine derivatives having the formula depicted in claim 1 with R3 being azatricyclooctyl; compositions containing the same and methods making use of them.

5. Claims: 1-30

Xanthine derivatives having the formula depicted in claim 1 with R3 being heterobicyclooctyl; compositions containing the same and methods making use of them.

6. Claim : 31

Process for making 8-substituted xanthines comprising the specific steps a) to e).

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/31100

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 4019892 A	02-01-1992	CA 2064742 A	23-12-1991
		WO 9200297 A	09-01-1992
		EP 0487673 A	03-06-1992
		JP 5501265 T	11-03-1993
		KR 186008 B	15-04-1999
		US 5641784 A	24-06-1997

EP 0415456 A	06-03-1991	AT 139778 T	15-07-1996
		BR 1100762 A	14-03-2000
		CA 2024381 A,C	02-03-1991
		CY 2069 A	11-09-1998
		DE 69027562 D	01-08-1996
		DE 69027562 T	20-02-1997
		DK 415456 T	29-07-1996
		ES 2091212 T	01-11-1996
		GR 3020715 T	30-11-1996
		HK 1000600 A	09-04-1998
		JP 1971274 C	27-09-1995
		JP 3173889 A	29-07-1991
		JP 6102662 B	14-12-1994
		US 5525607 A	11-06-1996
		US 5290782 A	01-03-1994
